

## Literatura

- 1 GI Motility online. Available from: [www.nature.com/gimo/index.html](http://www.nature.com/gimo/index.html).
- 2 Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? *Ann Intern Med* 1992;117(12):977-82.
- 3 Van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. *Gastroenterology* 2000;119(6):1439-46.
- 4 Poudroux P, Verdier E, Kahrilas PJ. Patterns of esophageal inhibition during swallowing, pharyngeal stimulation, and transient LES relaxation. Lower esophageal sphincter. *Am J Physiol Gastrointest Liver Physiol* 2003;284(2):G242-7.
- 5 Schoeman MN, Holloway RH. Integrity and characteristics of secondary oesophageal peristalsis in patients with gastro-oesophageal reflux disease. *Gut* 1995;36(4):499-504.
- 6 Mittal RK, Chiareli C, Liu J, Shaker R. Characteristics of lower esophageal sphincter relaxation induced by pharyngeal stimulation with minute amounts of water. *Gastroenterology* 1996;111 (2):378-84.
- 7 Wyman JB, Dent J, Heddl R, Dodds WJ, Toouli J, Downton J. Control of belching by the lower oesophageal sphincter. *Gut* 1990;31(6):639-46.
- 8 Dent J, Dodds WJ, Friedman RH, *et al.* Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980;65(2):256-67.
- 9 Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. *Am J Physiol* 1995;268(1 Pt 1):G128-33.
- 10 Holloway RH, Boeckxstaens GE, Penagini R, Sifrim D, Smout A, Ruth M. T1229 objective definition and detection of transient lower esophageal relaxation revisited: is there room for improvement? *Gastroenterology* 2009;136(5, Suppl 1):A-527.
- 11 Franzi SJ, Martin CJ, Cox MR, Dent J. Response of canine lower esophageal sphincter to gastric distension. *Am J Physiol* 1990;259(3 Pt 1):G380-5.
- 12 Straathof JWA, van Veen MM, Masclee AAM. Provocation of transient lower esophageal sphincter relaxations during continuous gastric distension. *Scand J Gastroenterol* 2002;37(10):1140-3.
- 13 Scheffer RCH, Akkermans LMA, Bais JE, Roelofs JMM, Smout AJPM, Gooszen HG. Elicitation of transient lower oesophageal sphincter relaxations in response to gastric distension and meal ingestion. *Neurogastroenterol Motil* 2002;14(6):647-55.
- 14 Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. *Gastroenterology* 1995;109(2):601-10.

- 15 Mittal RK, Fisher MJ. Electrical and mechanical inhibition of the crural diaphragm during transient relaxation of the lower esophageal sphincter. *Gastroenterology* 1990;99(5):1265-8.
- 16 Shi G, Pandolfino JE, Joehl RJ, Brasseur JG, Kahrilas PJ. Distinct patterns of oesophageal shortening during primary peristalsis, secondary peristalsis and transient lower oesophageal sphincter relaxation. *Neurogastroenterol Motil* 2002;14(5):505-12.
- 17 Babaei A, Bhargava V, Korsapati H, Zheng WH, Mittal RK. A unique longitudinal muscle contraction pattern associated with transient lower esophageal sphincter relaxation. *Gastroenterology* 2008;134(5):1322-31.
- 18 Kuribayashi S, Massey BT, Hafeezullah M, *et al.* Terminating motor events for TLESR are influenced by the presence and distribution of refluxate. *Am J Physiol Gastrointest Liver Physiol* 2009;297(1):G71-5.
- 19 Holloway RH, Kocyan P, Dent J. Provocation of transient lower esophageal sphincter relaxations by meals in patients with symptomatic gastroesophageal reflux. *Dig Dis Sci* 1991;36(8):1034-9.
- 20 Van Herwaarden MA, Katzka DA, Smout AJ, Samsom M, Gideon M, Castell DO. Effect of different recumbent positions on postprandial gastroesophageal reflux in normal subjects. *Am J Gastroenterol* 2000;95(10):2731-6.
- 21 Freidin N, Fisher MJ, Taylor W, *et al.* Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. *Gut* 1991;32(11):1275-9.
- 22 Martin CJ, Patrikios J, Dent J. Abolition of gas reflux and transient lower esophageal sphincter relaxation by vagal blockade in the dog. *Gastroenterology* 1986; 91(4):890-6.
- 23 Kalia M, Mesulam MM. Brain stem projections of sensory and motor components of the vagus complex in the cat: II. Laryngeal, tracheobronchial, pulmonary, cardiac, and gastrointestinal branches. *J Comp Neurol* 1980;193(2):467-508.
- 24 Rinaman L, Card JP, Schwaber JS, Miselis RR. Ultrastructural demonstration of a gastric monosynaptic vagal circuit in the nucleus of the solitary tract in rat. *J Neurosci* 1989;9(6):1985-96.
- 25 Rossiter CD, Norman WP, Jain M, Hornby PJ, Benjamin S, Gillis RA. Control of lower esophageal sphincter pressure by two sites in dorsal motor nucleus of the vagus. *Am J Physiol* 1990;259(6 Pt 1):G899-906.
- 26 Niedringhaus M, Jackson PG, Evans SRT, Verbalis JG, Gillis RA, Sahibzada N. Dorsal motor nucleus of the vagus: a site for evoking simultaneous changes in crural diaphragm activity, lower esophageal sphincter pressure, and fundus tone. *Am J Physiol Regul Integr Comp Physiol* 2008;294(1):R121-31.
- 27 Young RL, Page AJ, Cooper NJ, Frisby CL, Blackshaw LA. Sensory and motor innervation of the crural diaphragm by the vagus nerves. *Gastroenterology* 2010;138(3):1091-101.
- 28 Yuan S, Costa M, Brookes SJ. Neuronal pathways and transmission to the lower esophageal sphincter of the guinea pig. *Gastroenterology* 1998;115(3):661-71.

- 29 Kessing BF, Conchillo JM, Bredenoord AJ, Smout AJPM, Masclee AAM. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2011;33(6):650-61.
- 30 Yuan CS, Liu D, Attele AS. GABAergic effects on nucleus tractus solitarius neurons receiving gastric vagal inputs. *J Pharmacol Exp Ther* 1998;286(2):736-41.
- 31 Blackshaw LA, Smid SD, O'Donnell TA, Dent J. GABA(B) receptor-mediated effects on vagal pathways to the lower oesophageal sphincter and heart. *Br J Pharmacol* 2000;130(2):279-88.
- 32 Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. *J Neurochem* 2000;75(3):889-907.
- 33 Young RL, Page AJ, O'Donnell TA, Cooper NJ, Blackshaw LA. Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5. *Am J Physiol Gastrointest Liver Physiol* 2007;292(2):G501-11.
- 34 Van Sickle MD, Oland LD, Ho W, *et al.* Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. *Gastroenterology* 2001;121(4):767-74.
- 35 Bredenoord AJ, Weusten BLAM, Timmer R, Smout AJPM. Gastro-oesophageal reflux of liquids and gas during transient lower oesophageal sphincter relaxations. *Neurogastroenterol Motil* 2006;18(10):888-93.
- 36 Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful? *Am J Gastroenterol* 2001;96(9):2529-32.
- 37 Frankhuisen R, van Herwaarden MA, Scheffer RC, Hebbard GS, Gooszen HG, Samsom M. Increased intragastric pressure gradients are involved in the occurrence of acid reflux in gastroesophageal reflux disease. *Scand J Gastroenterol* 2009;44(5):545-50.
- 38 Pandolfino JE, Shi G, Curry J, Joehl RJ, Brasseur JG, Kahrilas PJ. Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. *Am J Physiol Gastrointest Liver Physiol* 2002;282(6):G1052-8.
- 39 Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. *Gastroenterology* 2003;125(4):1018-24.
- 40 Wu JCY, Mui LM, Cheung CMY, Chan Y, Sung JYJ. Obesity is associated with increased transient lower esophageal sphincter relaxation. *Gastroenterology* 2007;132(3):883-9.
- 41 Cohen S, Harris LD. Does hiatus hernia affect competence of the gastroesophageal sphincter? *N Engl J Med* 1971 13;284(19):1053-6.
- 42 Dodds WJ, Dent J, Hogan WJ, *et al.* Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. *N Engl J Med* 1982;307(25):1547-52.
- 43 Kasapidis P, Vassilakis JS, Tzovaras G, Chrysos E, Xynos E. Effect of hiatal hernia on esophageal manometry and pH-metry in gastroesophageal reflux disease. *Dig Dis Sci* 1995;40(12):2724-30.

- 44 Mattioli S, d'Ovidio F, di Simone MP, *et al.* Clinical and surgical relevance of the progressive phases of intrathoracic migration of the gastroesophageal junction in gastroesophageal reflux disease. *J Thorac Cardiovasc Surg* 1998;116(2):267-75.
- 45 Jones MP, Sloan SS, Jovanovic B, Kahrilas PJ. Impaired egress rather than increased access: an important independent predictor of erosive oesophagitis. *Neurogastroenterol Motil* 2002;14(6):625-31.
- 46 Patti MG, Goldberg HI, Arcerito M, Bortolasi L, Tong J, Way LW. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. *Am J Surg* 1996;171(1):182-6.
- 47 Berstad A, Weberg R, Frøyshov Larsen I, Hoel B, Hauer-Jensen M. Relationship of hiatus hernia to reflux oesophagitis. A prospective study of coincidence, using endoscopy. *Scand J Gastroenterol* 1986;21(1):55-8.
- 48 Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. *Am J Gastroenterol* 1999;94(8):2054-9.
- 49 Kahrilas PJ, Lin S, Chen J, Manka M. The effect of hiatus hernia on gastro-oesophageal junction pressure. *Gut* 1999;44(4):476-82.
- 50 Bredenoord AJ, Weusten BLAM, Timmer R, Smout AJPM. Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure. *Am J Gastroenterol* 2006;101(11):2470-5.
- 51 Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. *Gastroenterology* 1987;92(1):130-5.
- 52 Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. *Gastroenterology* 1991;100(3):596-605.
- 53 McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. *Gastroenterology* 1981;80(2):285-91.
- 54 Shay SS, Egli D, McDonald C, Johnson LF. Gastric emptying of solid food in patients with gastroesophageal reflux. *Gastroenterology* 1987;92(2):459-65.
- 55 Carmagnola S, Fraquelli M, Cantu P, Conte D, Penagini R. Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease. *Scand J Gastroenterol* 2006;41(7):767-72.
- 56 Penagini R, Mangano M, Bianchi PA. Effect of increasing the fat content but not the energy load of a meal on gastro-oesophageal reflux and lower oesophageal sphincter motor function. *Gut* 1998;42(3):330-3.
- 57 Stacher G, Lenglinger J, Bergmann H, *et al.* Gastric emptying: a contributory factor in gastro-oesophageal reflux activity? *Gut* 2000;47(5):661-6.
- 58 Herculano JRL Jr, Troncon LE, Aprile LR, *et al.* Diminished retention of food in the proximal stomach correlates with increased acidic reflux in patients with gastroesophageal reflux disease and dyspeptic symptoms. *Dig Dis Sci* 2004;49(5):750-6.
- 59 Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. *Gastroenterology* 2001;121(4):775-83.

- 60 Beaumont H, Bennink RJ, de Jong J, Boeckxstaens GE. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. *Gut* 2010;59(4):441-51.
- 61 Katz LC, Just R, Castell DO. Body position affects recumbent postprandial reflux. *J Clin Gastroenterol* 1994;18(4):280-3.
- 62 Wajed SA, Streets CG, Bremner CG, DeMeester TR. Elevated body mass disrupts the barrier to gastroesophageal reflux; discussion 1018-9. *Arch Surg* 2001;136(9):1014-18.
- 63 Hong D, Khajanchee YS, Pereira N, Lockhart B, Patterson EJ, Swanstrom LL. Manometric abnormalities and gastroesophageal reflux disease in the morbidly obese. *Obes Surg* 2004;14(6):744-9.
- 64 Suter M, Dorta G, Giusti V, Calmes JM. Gastro-esophageal reflux and esophageal motility disorders in morbidly obese patients. *Obes Surg* 2004;14(7):959-66.
- 65 El-Serag HB, Ergun GA, Pandolfino J, Fitzgerald S, Tran T, Kramer JR. Obesity increases oesophageal acid exposure. *Gut* 2007;56(6):749-55.
- 66 Corley DA. Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? *Gut* 2007;56(11):1493-4.
- 67 Crowell MD, Bradley A, Hansel S, *et al.* Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. *Am J Gastroenterol* 2009;104(3):553-9.
- 68 Raiha I, Impivaara O, Seppala M, Knuts LR, Sourander L. Determinants of symptoms suggestive of gastroesophageal reflux disease in the elderly. *Scand J Gastroenterol* 1993;28(11):1011-14.
- 69 Chang CS, Poon SK, Lien HC, Chen GH. The incidence of reflux esophagitis among the Chinese. *Am J Gastroenterol* 1997;92(4):668-71.
- 70 Jaffin BW, Knoepflmacher P, Greenstein R. High prevalence of asymptomatic esophageal motility disorders among morbidly obese patients. *Obes Surg* 1999;9(4):390-5.
- 71 Lagergren J, Bergstrom R, Nyren O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. *Gut* 2000;47(1):26-9.
- 72 Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. *Am J Gastroenterol* 2004;99(9):1807-14.
- 73 Blondeau K, van Oudenhove L, Farre R, *et al.* T1682 increasing body weight is associated with a higher incidence and proximal extent of reflux in patients with GERD Both 'on' and 'off' PPI therapy. *Gastroenterology* 2010;138(5, Suppl 1):S-556.
- 74 O'Brien TF Jr. Lower esophageal sphincter pressure (LESP) and esophageal function in obese humans. *J Clin Gastroenterol* 1980;2(2):145-8.
- 75 Stene-Larsen G, Weberg R, Froyshov Larsen I, Bjortuft O, Hoel B, Berstad A. Relationship of overweight to hiatus hernia and reflux oesophagitis. *Scand J Gastroenterol* 1988;23(4):427-32.

- 76 Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. *Am J Gastroenterol* 1999;94(10):2840-4.
- 77 Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. *Gastroenterology* 2006;130(3):639-49.
- 78 Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med* 2005 2; 143(3):199-211.
- 79 Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. *N Engl J Med* 2006;354(22):2340-8.
- 80 El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in *Helicobacter pylori*-negative patients with gastroesophageal reflux disease. *Scand J Gastroenterol* 2002;37(8):899-904.
- 81 Kjellin A, Ramel S, Rossner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. *Scand J Gastroenterol* 1996;31(11):1047-51.
- 82 Mathus-Vliegen EMH, van Weeren M, van Eerten PV. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. *Digestion* 2003;68(2-3):161-8.
- 83 De Groot NL, Burgerhart JS, van de Meeberg PC, de Vries DR, Smout AJPM, Siersema PD. Systematic review: the effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2009;30(11-12):1091-102.
- 84 Weusten BL, Roelofs JM, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. *Gastroenterology* 1994;107(6):1741-5.
- 85 Colas-Atger E, Bonaz B, Papillon E, *et al.* Relationship between acid reflux episodes and gastroesophageal reflux symptoms is very inconstant. *Dig Dis Sci* 2002;47(3):645-51.
- 86 Bredenoord AJ, Weusten BLAM, Curvers WL, Timmer R, Smout AJPM. Determinants of perception of heartburn and regurgitation. *Gut* 2006;55(3):313-18.
- 87 Weusten BL, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. *Gastroenterology* 1995;108(6):1739-44.
- 88 Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. *Gastroenterology* 1989;96(3):683-9.
- 89 Hemmink GJM, Bredenoord AJ, Weusten BLAM, Monkelbaan JF, Timmer R, Smout AJPM. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: “on” or “off” proton pump inhibitor? *Am J Gastroenterol* 2008;103(10):2446-53.
- 90 Mamie I, Tutuian R, Shay S, *et al.* Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006;55(10):1398-402.

- 91 Emerenziani S, Sifrim D, Habib FI, *et al.* Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. *Gut* 2008;57(4):443-7.
- 92 Logan KR, Hopwood D, Milne G. Cellular junctions in human oesophageal epithelium. *J Pathol* 1978;126(3):157-63.
- 93 Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. *Gastroenterology* 1970;58(2):163-74.
- 94 Hopwood D, Milne G, Logan KR. Electron microscopic changes in human oesophageal epithelium in oesophagitis. *J Pathol* 1979;129(4):161-7.
- 95 Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. *Gastroenterology* 1996;111(5): 1200-5.
- 96 Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. *Gastroenterology* 2005;128(3):771-8.
- 97 Calabrese C, Fabbri A, Bortolotti M, *et al.* Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. *Aliment Pharmacol Ther* 2003;18(5):525-32.
- 98 Caviglia R, Ribolsi M, Gentile M, *et al.* Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2007;25(5):629-36.
- 99 Van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. *Am J Gastroenterol* 2008;103(4):1021-8.
- 100 Villanacci V, Grigolato PG, Cestari R, *et al.* Dilated intercellular spaces as markers of reflux disease: histology, semiquantitative score and morphometry upon light microscopy. *Digestion* 2001;64(1):1-8.
- 101 Zentilin P, Savarino V, Mastracci L, *et al.* Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. *Am J Gastroenterol* 2005;100(10):2299-306.
- 102 Solcia E, Villani L, Luinetti O, *et al.* Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. *Virchows Arch* 2000;436(3):207-16.
- 103 Cui R, Zhou L, Lin S, *et al.* The feasibility of light microscopic measurements of intercellular spaces in squamous epithelium in the lower-esophagus of GERD patients. *Dis Esophagus* 2011;24(1):1-5.
- 104 Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. *Am J Gastroenterol* 2004;99(1):13-22.
- 105 Tobey NA, Hosseini SS, Caymaz-Bor C, Wyatt HR, Orlando GS, Orlando RC. The role of pepsin in acid injury to esophageal epithelium. *Am J Gastroenterol* 2001;96(11):3062-70.
- 106 Farre R, Fornari F, Blondeau K, *et al.* Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. *Gut* 2010;59(2):164-9.

- 107 Bove M, Vieth M, Dombrowski F, Ny L, Ruth M, Lundell L. Acid challenge to the human esophageal mucosa: effects on epithelial architecture in health and disease. *Dig Dis Sci* 2005;50(8):1488-96.
- 108 Calabrese C, Bortolotti M, Fabbri A, *et al.* Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. *Am J Gastroenterol* 2005;100(3):537-42.
- 109 Fass R, Naliboff BD, Fass SS, *et al.* The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. *Gastroenterology* 2008;134(3):696-705.
- 110 Farre R, de Vos R, Geboes K, *et al.* Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. *Gut* 2007;56(9):1191-7.
- 111 Anand P, Aziz Q, Willert R, van Oudenhove L. Peripheral and central mechanisms of visceral sensitization in man. *Neurogastroenterol Motil* 2007;19(1 Suppl):29-46.
- 112 Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. *Gut* 2008;57(5):674-83.
- 113 Bhat YM, Bielefeldt K. Capsaicin receptor (TRPV1) and non-erosive reflux disease. *Eur J Gastroenterol Hepatol* 2006;18(3):263-70.
- 114 Guarino MPL, Cheng L, Ma J, *et al.* Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. *Neurogastroenterol Motil* 2010;22(7):746-51.
- 115 Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitisation to the development of non-cardiac chest pain. *Lancet* 2000;356(9236):1154-9.
- 116 Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. *Am J Physiol Gastrointest Liver Physiol* 2001;281(3):G743-51.
- 117 Balaban DH, Yamamoto Y, Liu J, *et al.* Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. *Gastroenterology* 1999;116(1):29-37.
- 118 De Vries DR, ter Linde JJM, van Herwaarden MA, Smout AJPM, Samsom M. Gastroesophageal reflux disease is associated with the C825T polymorphism in the G-protein beta3 subunit gene (GNB3). *Am J Gastroenterol* 2009;104(2):281-5.



## Literatura

- 1 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101(8):1900-20.
- 2 Kahrilas PJ, Shaheen NJ, Vaezi MF, American Gastroenterological Association Institute. Technical review on the management of gastroesophageal reflux disease. *Gastroenterology* 2008;135(4):1392-413.
- 3 Dent J, Vakil N, Jones R, *et al.* Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond study. *Gut* 2010;59(6):714-21.
- 4 Wiklund I, Carlsson J, Vakil N. Gastro-esophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. *Am J Gastroenterol* 2006;101(1):18-28.
- 5 Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. *Clin Gastroenterol Hepatol* 2006;4(4):398-407.
- 6 Dent J, El-Serag H, Wallander M, Johansson S. Epidemiology of gastroesophageal reflux disease: a systematic review. *Gut* 2005;54:710-17.
- 7 Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. *Aliment Pharmacol Ther* 2004;20(7):751-60.
- 8 Ruigomez A, Wallander AM, Lundborg P, Johansson S, Garcia Rodriguez L. Gastroesophageal reflux disease in children and adults in primary care. *Scand J Gastroenterol* 2010;45:139-46.
- 9 El-Serag HB, Gilger M, Carter J, Genta RM, Rabeneck L. Childhood GERD is a risk factor for GERD in adolescents and young adults. *Am J Gastroenterol* 2004;99(5):806-12.
- 10 Sherman PM, Hassall E, Fagundes-Neto U, *et al.* A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. *Am J Gastroenterol* 2009;104(5):1278-95.
- 11 Yuen E, Romney M, Toner RW, *et al.* Prevalence, knowledge and care patterns for gastro-esophageal reflux disease in United States minority populations. *Aliment Pharmacol Ther* 2010;32(5):645-54.
- 12 Rosaida MS, Goh KL. Gastro-esophageal reflux disease, reflux esophagitis and nonerosive reflux disease in a multiracial Asian population: a prospective endoscopy based study. *Eur J Gastroenterol Hepatol* 2004;16(5):495-501.
- 13 Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. *Gastroenterology* 2006;130(3):639-49.
- 14 Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA* 2003 2;290(1):66-72.

- 15 Corley DA, Kubo A, Levin TR, *et al.* Abdominal obesity and body mass index as risk factors for Barrett's esophagus. *Gastroenterology* 2007;133(1):34-41.
- 16 Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vhan TL. Central adiposity and risk of Barrett's esophagus. *Gastroenterology* 2007;133(2):403-11.
- 17 Garcia Rodriguez LA, Ruigomez A, Martin-Merino E, Johansson S, Wallander MA. Relationship between gastroesophageal reflux disease and COPD in UK primary care. *Chest* 2008;134(6):1223-30.
- 18 Pace F, Pallotta S, Tonini M, Vakil N, Bianchi Porro G. Systematic review: gastroesophageal reflux disease and dental lesions. *Aliment Pharmacol Ther* 2008; 27(12):1179-86.
- 19 El-Serag HB, Gilger M, Kuebel M, Rabeneck L. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. *Gastroenterology* 2001;121(6): 1294-9.
- 20 El-Serag HB, Hepworth EJ, Lee P, Sonnenberg A. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. *Am J Gastroenterol* 2001;96(7):2013-18.
- 21 Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. *Am J Med* 1998;104(3):252-8.
- 22 Revicki DA, Zodet MW, Joshua-Gotlib S, Levine D, Crawley JA. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. *Health Qual Life Outcomes* 2003;1:73.
- 23 Ronkainen J, Aro P, Storskrubb T, *et al.* Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population - the Kalixanda study. *Aliment Pharmacol Ther* 2006;23(12):1725-33.
- 24 Jones R, Horbach S, Sander P, Ryden-Bergsten T. Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease. *Pharmacoeconomics* 2003;21(15):1091-102.
- 25 Zhao Y, Encinosa W. *Gastroesophageal reflux disease (GERD) hospitalizations in 1998 and 2005: Statistical Brief #44*. Washington, DC: Agency for Health Care Policy and Research, 2006.
- 26 Fedorak RN, Veldhuyzen van Zanten S, Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastro-esophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. *Can J Gastroenterol* 2010;24(7):431-4.
- 27 Anonymous. Cost of drugs. Available at: [www.imshealth.com/portal/site/ims/menu-item.d248e29c86589c9c30e81c033208c22a/?vgnextoid=d690a27e9d5b-7210VgnVC M100000ed152ca2RCRD&vgnnextfmt=default](http://www.imshealth.com/portal/site/ims/menu-item.d248e29c86589c9c30e81c033208c22a/?vgnextoid=d690a27e9d5b-7210VgnVC M100000ed152ca2RCRD&vgnnextfmt=default).
- 28 Gosselin A, Luo R, Lohoues H, *et al.* The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. *Value Health* 2009;12(1):34-9.
- 29 Wahlquist P, Reilly M, Barkun A. Systematic review: the impact of gastro-esophageal reflux on work productivity. *Aliment Pharmacol Ther* 2006;24:259-72.

- 30 Lind T, Havelund T, Lundell L, *et al.* On demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis - a placebo- controlled randomized trial. *Aliment Pharmacol Ther* 1999;13:907-14.
- 31 Talley N, Lauritsen K, Tunturi-Hihnala H, *et al.* Esomeprazole 20 mg maintains symptom control in endoscopy-negative GERD. A randomized placebo-controlled trial of on-demand therapy for 6 months. *Aliment Pharmacol Ther* 2001;15:347-54.
- 32 Bojke L, Hornby E, Sculpher M. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. *Pharmacoeconomics* 2007;25:829-41.
- 33 Arguedas MR, Heudebert GR, Klapow JC, *et al.* Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. *Am J Gastroenterol* 2004;99:1023-8.
- 34 Galmiche JP, Hatlebakk J, Attwood S, *et al.*, LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. *JAMA* 2011;305(19):1969-77.
- 35 Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body mass index and symptoms of gastroesophageal reflux in women. *N Engl J Med* 2006;354(22):2340-8.
- 36 Becher A, Dent J. Systematic review: ageing and gastro-esophageal reflux disease symptoms, oesophageal function and reflux esophagitis. *Aliment Pharmacol Ther* 2011;33:442-54.
- 37 Labenz J, Nocon M, Lind T, *et al.* Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. *Am J Gastroenterol* 2006;101(11):2457-62.
- 38 Guda NM, Vakil N. Proton pump inhibitors and the time trends for esophageal dilation. *Am J Gastroenterol* 2004;99(5):797-800.
- 39 De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. *Gut* 2010;59(8):1030-6.
- 40 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340(11):825-31.

## Literatura

- 1 Locke GR III, Talley NJ, Fett SL *et al.* Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997;112:1448-56.
- 2 Lind T, Havelund T, Carlsson R, *et al.* Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. *Scand J Gastroenterol* 1997;32:974-9.
- 3 Vakil N, van Zanten SV, Kahrilas P, *et al.* The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900.
- 4 Klauser AG, Shcindelbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. *Lancet* 1990;335:205.
- 5 Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: a systematic review. *Gut* 2007;56:1654-64.
- 6 Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Am Rev Respir Dis* 1990;141:640-7.
- 7 El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. *Gastroenterology* 1997;113:755-60.
- 8 Stanghellini V, Arsmtrong D, Monnikes H, Bardhan KD. Systematic review: do we need a new gastroesophageal diseases questionnaire? *Digestion* 2007;75(suppl 1):3-16.
- 9 Numans ME, Lau J, de Wit NK, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. *Ann Intern Med* 2004; 140:518-52.
- 10 Johnston BT, Troshinsky MB, Castell JA, *et al.* Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. *Am J Gastroenterol* 1996;91:1181-5.
- 11 Thompson JK, Koehler RE, Richter JE. Detection of gastroesophageal reflux: value of barium studies compared with 24-hr pH monitoring. *Am J Roentgenol* 1994;162:621-6.
- 12 Richter JE, Castell DO. Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy. *Ann Intern Med* 1982;97:93-103.
- 13 Savarino E, Gemignani L, Pohl D, *et al.* Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2011;34:476-86.
- 14 Shaw J, Bornman PC, Callanan MD, Beckingham IJ, Metz DC. Long-term outcome of laparoscopic Nissen and laparoscopic Toupet fundoplication for

- gsatrosophageal reflux disease: a prospective, randomized trial. *Surg Endosc* 2010;24:924-32.
- 15 Lundell LR, Dent J, Bennett JR, *et al.* Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. *Gut* 1999;45:172-80.
  - 16 Johnsson F, Joelsson B, Gudmundsson K, *et al.* Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. *Scand J Gastroenterol* 1987; 22:714-18.
  - 17 Mokhashi MS, Wildi SM, Glenn TF, *et al.* A prospective, blinded study of diagnostic esophagoscopy with a superthin, stand-alone, battery-powered esophagoscope. *Am J Gastroenterol* 2003;98:2383.
  - 18 Eliakim R, Sharma VK, Yassin K, *et al.* A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. *J Clin Gastroenterol* 2005;39:572-8.
  - 19 Nandurkar S, Talley NJ, Martin CJ, Ng T, Adams S. Esophageal histology does not provide additional useful information over clinical assessment in identifying reflux patients presenting for esophagogastroduodenoscopy. *Dig Dis Sci* 2000;45:217-24.
  - 20 Tytgat G. The value of esophageal histology in the diagnosis of gastroesophageal reflux diseases in patients with heartburn and normal endoscopy. *Curr Gastroenterol Rep* 2008;10:231-4.
  - 21 Prasad GA, Talley NJ, Romero Y, *et al.* Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. *Am J Gastroenterol* 2007;102:2627.
  - 22 Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. *Gastroenterology* 1996;111:1192-9.
  - 23 Sun G, Muddana S, Slaughter JC, *et al.* A new pH catheter for laryngopharyngeal reflux: normal values. *Laryngoscope* 2009;119:1639-43.
  - 24 Johnson LF, DeMeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. *Am J Gastroenterol* 1974;62:325-32.
  - 25 Pandolfino JE, Vela MF. Esophageal reflux monitoring. *Gastrointest Endosc* 2009;69:917-30.
  - 26 Jamieson JR, Stein HJ, DeMeester TR, *et al.* Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. *Am J Gastroenterol* 1992;87:1102-11.
  - 27 Richter JE, Bradley LA, DeMeester TR, Wu WC. Normal 24-hr ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. *Dig Dis Sci* 1992;37:849-56.
  - 28 Schlesinger PK, Donahue PE, Schmid B, *et al.* Limitations of 24-hour intraesophageal pH monitoring in the hospital setting. *Gastroenterology* 1985;89:797-804.

- 29 Fass R, Hell R, Sampliner RE, *et al.* Effect of ambulatory 24-h esophageal pH monitoring on reflux-provoking activities. *Dig Dis Sci* 1999;44:2263-9.
- 30 Pandolfino J, Zhang Q, Schreiner M, *et al.* Acid reflux event detection using the Bravo™ wireless vs the Slimline™ catheter pH systems: why are the numbers so different? *Gut* 2005;54:1687-92.
- 31 Wenner J, Jonsson F, Johansson J, Oberg S. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized crossover trial. *Am J Gastroenterol* 2007;102:239-45.
- 32 Ward EM, Devault KR, Bouras EP, *et al.* Successful oesophageal pH monitoring with a catheter-free system. *Aliment Pharmacol Ther* 2004;19:449-54.
- 33 Hirano I, Zhang Q, Pandolfino JE, *et al.* Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. *Clin Gastroenterol Hepatol* 2005;3:1083-8.
- 34 Pandolfino JE, Richter JE, Ours T, *et al.* Ambulatory esophageal pH monitoring using a wireless system. *Am J Gastroenterol* 2003;984:740-9.
- 35 Vela MF. Non-acid reflux: detection by multichannel intraluminal impedance and pH, clinical significance and management. *Am J Gastroenterol* 2009;104:277-80.
- 36 Sifrim D, Castell D, Dent J, *et al.* Gastro-oesophageal reflux monitoring: reflux and consensus report on detection and definitions of acid, non-acid, and gas reflux. *Gut* 2004;53:1024-31.
- 37 Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Reproducibility of multichannel intraluminal electrical impedance monitoring of gastroesophageal reflux. *Am J Gastroenterol* 2005;100:265-9.
- 38 Shay S, Tutuian R, Sifrim D, *et al.* Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. *Am J Gastroenterol* 2004;99:1037-43.
- 39 Zerbib F, des Varannes SB, Roman S, *et al.* Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. *Aliment Pharmacol Ther* 2005;22:1011-21.
- 40 Vela MF, Camacho-Lobato L, Srinivasan R, *et al.* Intraesophageal impedance and pH measurement of acid and non-acid reflux: effect of omeprazole. *Gastroenterology* 2001;96:647-55.
- 41 Vela MF, Tutuian R, Katz PO, *et al.* Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. *Aliment Pharmacol Ther* 2003;17:243-51.
- 42 Frazzoni M, Conigliaro R, Melotti G. Reflux parameters as modified by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy: a study using impedance-pH monitoring. *Dig Dis Sci* 2011;56:1099-106.
- 43 Wiener GJ, Richter JE, Copper JB, *et al.* The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. *Am J Gastroenterol* 1988;83:358-61.

- 44 Weusten BL, Roelofs JM, Akkermans LM, *et al.* The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. *Gastroenterology* 1994;107:1741-5.
- 45 Singh S, Richter JE, Bradley LA, Haile JM. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. *Dig Dis Sci* 1993;34:309-16.
- 46 Connor J, Richter J. Increasing yield also increases false positives and best serves to exclude GERD. *Am J Gastroenterol* 2006;101:460-3.

## Literatura

- 1 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101(8):1900-20.
- 2 Sontag SJ, Sonnenberg A, Schnell TG, Leya J, Metz A. The long-term natural history of gastroesophageal reflux disease. *J Clin Gastroenterol* 2006;40(5):398-404.
- 3 Pandolfino JE, Kwiatek MA, Kahrilas PJ. The pathophysiologic basis for epidemiologic trends in gastroesophageal reflux disease. *Gastroenterol Clin North Am* 2008;37(4):827-43, viii.
- 4 Kahrilas PJ, Shaheen NJ, Vaezi MF, *et al.* American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology* 2008;135(4):1383-91.
- 5 Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med* 2005 2;143(3):199-211.
- 6 Kjellin A, Ramel S, Rossner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. *Scand J Gastroenterol* 1996;31(11):1047-51.
- 7 Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. *Scand J Gastroenterol* 1999;34(4):337-40.
- 8 Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. *N Engl J Med* 2006; 354(22):2340-8.
- 9 Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. *Cochrane Database Syst Rev* 2007;2:CD003244.
- 10 Van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro- oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. *Cochrane Database Syst Rev* 2010;11:CD002095.
- 11 Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. *Clin Gastroenterol Hepatol* 2004;2(8):665-8.
- 12 Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. *Am J Gastroenterol* 2011;106(8):1419-25.
- 13 Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro- oesophageal reflux disease. *Gut* 2011;60(11):1473-8.



- 14 Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. *Cochrane Database Syst Rev* 2011;1:CD004823.
- 15 Sifrim D, Holloway R, Silny J, Tack J, Lerut A, Janssens J. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. *Am J Gastroenterol* 2001;96(3):647-55.
- 16 Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. *Gut* 2002;50(1):19-24.
- 17 Gerson LB, Huff FJ, Hila A, *et al.* Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. *Am J Gastroenterol* 2010; 105(6):1266-75.
- 18 Boeckstaens GE, Beaumont H, Mertens V, *et al.* Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. *Gastroenterology* 2010;139(2):409-17.
- 19 Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. *Gut* 2003;52(4):464-70.
- 20 Boeckstaens GE, Beaumont H, Hatlebakk JG, *et al.* A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo- controlled trial. *Gut* 2011;60(9):1182-8.
- 21 Dicipinigaitis PV, Dobkin JB. Antitussive effect of the GABA-agonist baclofen. *Chest* 1997;111(4):996-9.
- 22 Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure. *Am J Gastroenterol* 2006;101(11):2470-5.
- 23 Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. *Gastroenterology* 1991;100(3):596-605.
- 24 Lin S, Ke M, Xu J, Kahrilas PJ. Impaired esophageal emptying in reflux disease. *Am J Gastroenterol* 1994;89(7):1003-6.
- 25 Durazo FA, Valenzuela JE. Effect of single and repeated doses of metoclopramide on the mechanisms of gastroesophageal reflux. *Am J Gastroenterol* 1993;88(10): 1657-62.
- 26 Matysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. *Aliment Pharmacol Ther* 2003;18(Suppl 1):55-62.
- 27 Yoshida N, Kamada K, Tomatsuri N, *et al.* Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. *Dig Dis Sci* 2010;55(12):3393-8.
- 28 Majewski M, Jaworski T, Sarosiek I, *et al.* Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect. *Clin Gastroenterol Hepatol* 2007;5(4):430-8.

- 29 Zeng J, Zuo XL, Li YQ, Wei W, Lv GP. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study. *Eur J Clin Pharmacol* 2007;63(6):529-36.
- 30 Yang M, Li ZS, Chen DF, *et al.* Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. *Clin J Pain* 2010;26(4):326-31.
- 31 Nasr I, Attaluri A, Hashmi S, Gregersen H, Rao SS. Investigation of esophageal sensation and biomechanical properties in functional chest pain. *Neurogastroenterol Motil* 2010;22(5):520-6.
- 32 Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. *Dig Dis Sci* 1999;44(12):2373-9.
- 33 Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. *Gastroenterology* 1987;92(4):1027-36.
- 34 Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2006;23(3):365-70.
- 35 Viazis N, Keyoglou A, Kanellopoulos AK, *et al.* Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. *Am J Gastroenterol* 2011; May 31 (epub ahead of print).
- 36 Dickman R, Schiff E, Holland A, *et al.* Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. *Aliment Pharmacol Ther* 2007; 26(10):1333-44.
- 37 Nojkov B, Rubenstein JH, Adlis SA, *et al.* The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2008;27(6):473-82.
- 38 Kiebles JL, Kwiatek MA, Pandolfino JE, Kahrilas PJ, Keefer L. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. *Dis Esophagus* 2010;23(7):545-53.
- 39 Lundell L, Attwood S, Ell C, *et al.* Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. *Gut* 2008;57(9):1207-13.
- 40 Galmiche JP, Hatlebakk J, Attwood S, *et al.* Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD. The LOTUS randomized clinical trial. *JAMA* 2011;305(19):1969-77.
- 41 Pandolfino JE, Kahrilas PJ. AGA technical review on the clinical use of esophageal manometry. *Gastroenterology* 2005;128(1):209-24.
- 42 Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. *Am J Med* 2003;114(1):1-5.

- 43 Hunter JG, Smith CD, Branum GD, *et al.* Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. *Ann Surg* 1999;230(4):595-604; discussion 606.
- 44 Bell RC, Cadiere GB. Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations. *Surg Endosc* 2011;25(7):2387-99.
- 45 Frazzoni M, Conigliaro R, Manta R, Melotti G. Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD. *Aliment Pharmacol Ther* 2011;34(1):67-75.
- 46 Testoni PA, Corsetti M, di Pietro S, *et al.* Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. *World J Surg* 2010;34(4):750-7.
- 47 Bonavina L, DeMeester T, Fockens P, *et al.* Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. *Ann Surg* 2010;252(5):857-62.
- 48 Vaezi MF, Richter JE, Stasney CR, *et al.* Treatment of chronic posterior laryngitis with esomeprazole. *Laryngoscope* 2006;116(2):254-60.

## Literatura

- 1 Gatyas G. IMS Health Reports 2009. Available at: [www.imshealth.com](http://www.imshealth.com).
- 2 Bezwoda W, Charlton R, Bothwell T, *et al.* The importance of gastric hydrochloric acid in the absorption of nonheme food iron. *J Lab Clin Med* 1978;92:108-16.
- 3 Conrad ME, Schade SG. Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile. *Gastroenterology* 1968;55:35-43.
- 4 McColl KE. Effect of proton pump inhibitors on vitamins and iron. *Am J Gastroenterol* 2009;104(Suppl 2):S5-S9.
- 5 Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. *Aliment Pharmacol Ther* 1992;6:399-406.
- 6 Wright MJ, Sullivan RR, Gaffney-Stomberg E, *et al.* Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. *J Bone Miner Res* 2010;25:2205-11.
- 7 Hansen KE, Jones AN, Lindstrom JM, *et al.* Do proton pump inhibitors decrease calcium absorption? *J Bone Miner Res* 2010;25:2510-19.
- 8 [www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsand providers/ucm213206.htm](http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm)
- 9 Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. *Calcif Tissue Int* 2006;79:76-83.
- 10 Yang YX, Lewis JD, Epstein S, *et al.* Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA* 2006;296:2947-53.
- 11 Targownik LE, Lix LM, Metge CJ, *et al.* Use of proton pump inhibitors and risk of osteoporosis-related fractures. *CMAJ* 2008;179:319-26.
- 12 Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. *Gastroenterology* 2010;139:93-101.
- 13 Laine L. Proton pump inhibitors and bone fractures? *Am J Gastroenterol* 2009; 104:S21-S26.
- 14 Johnson DA. Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents. *Curr Gastroenterol Rep* 2010;12:167-74.
- 15 Targownik LE, Lix LM, Leung S, Leslies WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. *Gastroenterology* 2010;138:896-904.
- 16 Gray SL, LaCroix AZ, Larson J, *et al.* Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. *Arch Intern Med* 2010;170:765-71.
- 17 Jefferies KC, Cipriano DJ, Forgac M. Function structure and regulation of the vacuolar (H+) ATPases. *Arch Biochem Biophys* 2008;476:33-42.

- 18 Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H<sup>+</sup>, K<sup>+</sup>, ATPase on bone resorption in humans. *Calcif Tissue Int* 1993;53:21-5.
- 19 Epstein M, McGrath S, Law F. Proton pump inhibitors and hypomagnesemic hypoparathyroidism. *N Engl J Med* 2006;355:1834-6.
- 20 Broeren MAC, Geerdink EAM, Vader HL, *et al.* Hypomagnesemia induced by several proton pump inhibitors. *Ann Intern Med* 2009;151:755-6.
- 21 MacKay JD, Bladon PT. Hypomagnesemia due to proton pump inhibitor therapy: a clinical case series. *Q J Med* 2010;103(6):387-95.
- 22 [www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman-Medical-Products/ucm245275.htm](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman-Medical-Products/ucm245275.htm)
- 23 Yang YX, Metz DC. Safety of proton pump inhibitor exposure. *Gastroenterology* 2010;139:1115-27.
- 24 Gilard M, Arnaud B, Cornily JC, *et al.* Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) Study. *J Am Coll Cardiol* 2008;51:256-60.
- 25 Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? *Am J Gastroenterol* 2010;105:34-41.
- 26 Ho PM, Maddox TM, Wang L, *et al.* Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. *JAMA* 2009;301:937-44.
- 27 Ray WA, Murray KT, Griffin MR, *et al.* Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. *Ann Intern Med* 2010;152:337-45.
- 28 [www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor-Patientsand-Providers/DrugSafetyInformationforHealthcareProfessionals/ucm190784.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor-Patientsand-Providers/DrugSafetyInformationforHealthcareProfessionals/ucm190784.htm)
- 29 Bhatt DL, Scheiman J, Abraham NS, *et al.* American College of Cardiology Foundation, American College of Gastroenterology, American Heart Association. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *Am J Gastroenterol* 2008; 103:2890-907.
- 30 O'Donoghue ML, Braunwald E, Antman EM, *et al.* Pharmacodynamic effect and clinical efficacy efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. *Lancet* 2009;374:989-97.
- 31 Bhatt DL, Cryer BL, Contant CF *et al.*, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med* 2010;363:1909-17.
- 32 [www.fda.gov/Drugs/DrugSafety/ucm231161.htm](http://www.fda.gov/Drugs/DrugSafety/ucm231161.htm).
- 33 Juurlink DN, Gomes T, Marndarni MM, *et al.* The safety of proton pump inhibitors and clopidogrel in patients after stroke. *Stroke* 2011;42:128-32.

- 34 Abraham NS, Hlatky MA, Antman EM, *et al.* ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *Am J Gastroenterol* 2010;105:2533-49.
- 35 Banerjee S, Weideman RA, Weideman MW, *et al.* Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. *Am J Cardiol* 2011;107(6):871-8.
- 36 Chan FKL, Ching JYL, Hung LCT, *et al.* Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. *N Engl J Med* 2005;352:238-44.
- 37 Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. *Proc Natl Acad Sci USA* 2001;98:6470-5.
- 38 Hus PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence compared with clopidogrel alone, in patients with atherosclerosis. *Gastroenterology* 2011;140:791-8.
- 39 Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation and translocation of cytochrome b-245. *Gut* 1992;33:617-21.
- 40 Laheij RJ, Sturkenboom MD, Hassing RJ, *et al.* Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004;292:1955-60.
- 41 Gulmez SE, Holm A, Frederiksen H, *et al.* Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. *Arch Intern Med* 2007;167:950-5.
- 42 Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. *JAMA* 2009;301:2120-8.
- 43 Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. *Aliment Pharmacol Ther* 2010;31:1165-77.
- 44 Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. *Ann Intern Med* 2008;149:391-8.
- 45 Dublin A, Walker RL, Kackson ML, *et al.* Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. *Pharmacoepidemiol Drug Saf* 2010;19:792-802.
- 46 DuPont HL. Travellers' diarrhoea: contemporary approaches to therapy and prevention. *Drugs* 2006;66:303-14.
- 47 Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J, *et al.* Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. *Trop Med Int Health* 1998;3:896-903.
- 48 Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007;102:2047-56.
- 49 Dial MS. Proton pump inhibitor use and enteric infections. *Am J Gastroenterol* 2009;104(Suppl 2):S10-S16.

- 50 Howell MD, Novack V, Grgurich P, *et al.* Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. *Arch Intern Med* 2010;170:784-90.
- 51 Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. *Clin Gastroenterol Hepatol* 2010;8(6):504-8.
- 52 Bajaj JS, Zadvornova Y, Heuman DM, *et al.* Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. *Am J Gastroenterol* 2009;104:1130-4.
- 53 Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. *Dig Dis Sci* 2008;53:394-8.
- 54 Sierra F, Suarez M, Rey M, *et al.* Systematic review: proton pump inhibitor associated acute interstitial nephritis. *Aliment Pharmacol Ther* 2007;26:545-53.

## Literatura

- 1 Stefanidis D, Hope WW, Kohn GP, *et al.* Guidelines for surgical treatment of gastro-esophageal reflux disease. *Surg Endosc* 2010;24:2647-69.
- 2 Jensen CD, Gilliam AD, Horgan LF, *et al.* Day-care laparoscopic Nissen fundoplication. *Surg Endosc* 2009;23:1745-9.
- 3 Pizza F, Rossetti G, Limongelli P, *et al.* Influence of age on outcome of total laparoscopic fundoplication for gastroesophageal reflux disease. *World J Gastroenterol* 2007;13:740-7.
- 4 Finks JF, Wei Y, Birkmeyer JD. The rise and fall of antireflux surgery in the United States. *Surg Endosc* 2006;20:1698-701.
- 5 Wang YR, Dempsey DT, Richter JE. Trends and perioperative outcomes of inpatient antireflux surgery in the United States, 1993-2006. *Dis Esophagus* 2011;24(4):215-23.
- 6 Agency for Healthcare Research and Quality - the Effective Healthcare Program. *Comparative effectiveness of management strategies for gastroesophageal reflux disease - an update to the 2005 report.* Washington, DC: Agency for Healthcare Research and Quality, 2011.
- 7 Dominitz JA, Dire CA, Billingsley KG, Todd-Steinberg JA. Complications of antireflux medication use after antireflux surgery. *Clin Gastroenterol Hepatol* 2006;4:299-305.
- 8 Lundell L. Complications of anti-reflux surgery. *Best Pract Res Clin Gastroenterol* 2004;18(5):935-45.
- 9 Zacharoulis D, O'Boyle CJ, Sedman PC, *et al.* Laparoscopic fundoplication: a 10-year learning curve. *Surg Endosc* 2006;20:1662-70.
- 10 Carlson MA, Frantzides CT. Complications and results of primary minimally invasive antireflux procedures: a review of 10,735 reported cases. *J Am Coll Surg* 2001;193:428-39.
- 11 Bizakis C, Kent M, Luketich J. Complications after surgery for gastroesophageal reflux disease. *Thorac Surg Clin* 2006;16:99-108.
- 12 Neuhauser B, Hinder RA. Laparoscopic reoperation after failed antireflux surgery. *Semin Laparosc Surg* 2001;8:281-6.
- 13 Rantanen TK, Salo JA, Sipponer JT. Fatal and life-threatening complications in antireflux surgery: analysis of 5,502 operations. *Br J Surg* 1999;86:1573-7.
- 14 Flum DR, Koepsell T, Heagerty P, Pellegrini C. The nationwide frequency of major adverse outcome in antireflux surgery and the role of surgeon experience, 1992-1997. *J Am Coll Surg* 2002;195:611-18.
- 15 Rogers DM, Herrington JL, Morton C. Incidental splenectomy associated Nissen fundoplication. *Ann Surg* 1980;191:153-6.
- 16 Bradshaw WA, Gregory BC, Finley C, *et al.* Frequency of postoperative nausea and vomiting in patients undergoing laparoscopic foregut surgery. *Surg Endosc* 2002;16:777-80.



- 17 Meyers BF, Soper NJ. Complications of surgery for gastroesophageal reflux. In: Patterson GA, Cooper JD, Deslauriers J, Lerut AEMR, Luketic JD, Rice TW (eds) *Person's thoracic and esophageal surgery*, 3rd edn. Philadelphia: Churchill Livingstone, 2008: pp. 376-86.
- 18 Spechler SJ. The management of patients who have “failed” antireflux surgery. *Am J Gastroenterol* 2004;99:552-61.
- 19 Spechler SJ. Comparison of medical and surgical therapy for complicated GERD in veterans. Department of Veterans Affairs Gastroesophageal Reflux Study Group. *N Engl J Med* 1992;326:786-92.
- 20 McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastro-esophageal reflux disease. *Gastroenterology* 1981;80:285-91.
- 21 Bias JE, Samson M, Boudesteijn CG, *et al.* Impact of delayed gastric emptying on the outcome of antireflux surgery. *Ann Surg* 2001;234:139-46.
- 22 Wo JM, Trus TL, Richardson WS, *et al.* Evaluation and management of post fundoplication dysphagia. *Am J Gastroenterol* 1996;91:2318-22.
- 23 Fibbe C, Layer P, Keller J, *et al.* Esophageal motility in reflux disease before and after fundoplication: a prospective randomized, clinical and manometric study. *Gastroenterology* 2001;121:5-14.
- 24 Watson DL. Laparoscopic treatment of gastroesophageal reflux disease. *Best Pract Res Clin Gastroenterol* 2004;18:19-35.
- 25 Malki-Chowla N, Gorecki P, Bammer T, *et al.* Dilation after fundoplication: timing, frequency, indications and outcome. *Gastrointest Endosc* 2002;55:219-23.
- 26 Hui JM, Hunt DR, Carle DJ, *et al.* Esophageal pneumatic dilation for post fundoplication dysphagia: safety, efficacy and predictors of outcome. *Am J Med* 2002;97:2986-91.
- 27 Klaus A, Hinder RA, deVault KR, Achem SR. Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity and clinical course. *Am J Med* 2003; 114:6-9.
- 28 Swanstrom L, Wayne R. Spectrum of gastrointestinal symptoms after laparoscopic fundoplication. *Am J Surg* 1994;167:538-41.
- 29 Spechler SJ, Lee E, Ahnen D, *et al.* Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. *JAMA* 2001;285:2331-8.
- 30 Domintz JA, Dire C, Billingsley KG, Todd-Steinberg JA. Complications and antireflux medication use after antireflux surgery. *Clin Gastroenterol Hepatol* 2006; 4:299-305.
- 31 Lord RVN, Kaminski A, Oberg S, *et al.* Absence of gastroesophageal reflux disease in a majority of patients taking acid suppression medications after Nissen fundoplication. *J Gastrointest Surg* 2002;6:3-10.
- 32 Wijnhoven BPL, Lally CJ, Kelly JJ, *et al.* Use of antireflux medication after antireflux surgery. *J Gastrointest Surg* 2008;12:510-17.
- 33 Hunter JG, Smith CS, Branum GD, *et al.* Laparoscopic fundoplication failure: patterns of failure and response to fundoplication revision. *Ann Surg* 1999;23:595-606.

- 34 Hatch KF, Daily MF, Christiansen BJ, Glasgow RE. Failed funduplications. *Am J Surg* 2004;188:786-91.
- 35 Bizakis C, Kent M, Luketich J. Complications after surgery for gastroesophageal reflux disease. *Thorac Surg Clin* 2006;16:99-108.
- 36 Gastal OL, Hagen JA, Peters JH, *et al.* Short esophagus: analysis of predictors and clinical implications. *Arch Surg* 1999;134:633-6.
- 37 Smith CD, McClusky DA, Rajad MA, *et al.* When funduplications fails: redo? *Ann Surg* 2005;241:861-71.

## Literatura

- 1 El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. *Aliment Pharmacol Ther* 2010;32(6):720-37.
- 2 Castell DO, Kahrilas PJ, Richter JE, *et al.* Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. *Am J Gastroenterol* 2002;97(3):575-83.
- 3 Lind T, Havelund T, Carlsson R, *et al.* Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. *Scand J Gastroenterol* 1997;32(10):974-9.
- 4 Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. *Gastroenterology* 2009;136(2):376-86.
- 5 Tytgat GN, McColl K, Tack J, *et al.* New algorithm for the treatment of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2008;27(3):249-56.
- 6 Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. *Am J Gastroenterol* 2005;100(2):283-9.
- 7 Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? *Aliment Pharmacol Ther* 2005;22(2):79-94.
- 8 Savarino E, Pohl D, Zentilin P *et al.* Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. *Gut* 2009;58(9):1185-91.
- 9 Mainie I, Tutuian R, Shay S, *et al.* Add and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006;55(10):1398-402.
- 10 El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. *Am J Gastroenterol* 2009;104(9):2161-7.
- 11 Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. *Br J Gen Pract* 1999;49(443):463-4.
- 12 Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2006;23(10):1473-7.
- 13 Kahrilas PJ, Shaheen NJ, Vaezi MF, *et al.* American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology* 2008;135(4):1383-91.
- 14 Vakil N. Review article: test and treat or treat and test in reflux disease? *Aliment Pharmacol Ther* 2003;17(Suppl 2):57-9.

- 15 Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. *Clin Gastroenterol Hepatol* 2006;4(1):50-6.
- 16 Pandolfino JE, Vela MF. Esophageal-reflux monitoring. *Gastrointest Endosc* 2009;69(4):917-30.
- 17 Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. *Neurogastroenterol Motil* 2011;23(5):419-26.
- 18 Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. *Clin Gastroenterol Hepatol* 2009;7(7):743-8.
- 19 Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. *Am J Gastroenterol* 2008;103(7):1631-7.
- 20 Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. *Dis Esophagus* 2005;18(6):370-3.
- 21 Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. *Aliment Pharmacol Ther* 2007;26(10):1355-60.
- 22 Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. *Aliment Pharmacol Ther* 1998;12(12):1235-40.
- 23 Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. *Gastroenterology* 2002;122(3):625-32.
- 24 Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. *Aliment Pharmacol Ther* 2003;17(2):243-51.
- 25 Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. *Gut* 2003;52(10):1397-402.
- 26 Gerson LB, Huff FJ, Hila A, *et al.* Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. *Am J Gastroenterol* 2010;105(6): 1266-75.
- 27 Boeckxstaens GE, Beaumont H, Mertens V, *et al.* Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. *Gastroenterology* 2010;139(2):409-17.
- 28 Durazo FA, Valenzuela JE. Effect of single and repeated doses of metoprolol on the mechanisms of gastroesophageal reflux. *Am J Gastroenterol* 1993;88(10):1657-62.
- 29 Yang M, Li ZS, Chen DF, *et al.* Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid

- perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. *Clin J Pain* 2010;26(4):326-31.
- 30 Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2006;23(3):365-70.
- 31 Nasr I, Attaluri A, Hashmi S, Gregersen H, Rao SS. Investigation of esophageal sensation and biomechanical properties in functional chest pain. *Neurogastroenterol Motil* 2010;22(5):520-6.
- 32 Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. *Gut* 1995;37 (4):457-64.
- 33 Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. *Gut* 2002;51(6):885-92.
- 34 Dickman R, Schiff E, Holland A, *et al.* Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. *Aliment Pharmacol Ther* 2007;26(10):1333-44.
- 35 Nojkov B, Rubenstein JH, Adlis SA, *et al.* The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2008;27(6):473-82.
- 36 Rubenstein JH, Nojkov B, Korsnes S, *et al.* Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. *Aliment Pharmacol Ther* 2007;26(3):443-52.
- 37 Jones H, Cooper P, Miller V, Brooks N, Whorwell PJ. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. *Gut* 2006;55(10):1403-8.
- 38 Broeders JA, Draaisma WA, Bredenoord AJ, Smout AJ, Broeders IA, Gooszen HG. Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro- oesophageal reflux disease. *Br J Surg* 2010;97(6):845-52.
- 39 Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intra-luminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. *Br J Surg* 2006;93(12): 1483-7.

## Literatura

- 1 Locke GR, Talley NJ, Fett SL, *et al.* Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997;112:1448-56.
- 2 Dent J, Armstrong D, Delanye B, *et al.* Symptom evaluation in reflux disease: workshop, background, process, terminology, recommendations and discussion outputs. *Gut* 2004;53:iv1-iiiv24.
- 3 Carlsson R, Dent J, Bolling-Sternevalde E, *et al.* The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. *Scand J Gastroenterol* 1998;33:1023-9.
- 4 Zerbib F, Roman S, Ropert A, *et al.* Esophageal pH-impedance monitoring and symptom analysis in GERD. A study in patients off and on therapy. *Am J Gastroenterol* 2006;101:1956-63.
- 5 Sifrim D, Castell D, Dent J, *et al.* Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. *Gut* 2004;53:1024-31.
- 6 Karamanolis G, Stevens W, Vos R, *et al.* Oesophageal tone and sensation in the transition zone between proximal striated and distal smooth muscle oesophagus. *Neurogastroenterol Motil* 2008;20:291-7.
- 7 Clouse RE, Richter JE, Heading RC, *et al.* Functional esophageal disorders. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (eds) *Rome II. The functional gastrointestinal disorders*, 2nd edn. McLean, VA: Degnon Associates, 2000: pp. 247-98.
- 8 Galmiche JP, Clouse RA, Balint A, *et al.* Functional esophageal disorders. *Gastroenterology* 2006;130:1459-65.
- 9 Galmiche JP, Clouse RE, Balint A, *et al.* Functional esophageal disorders. In: Drossman DA, Corazziari E, Spiller R, *et al.* (eds) *Rome III. The functional gastrointestinal disorders*, 3rd edn. McLean, VA: Degnon Associates, 2006: pp. 369-418.
- 10 Shi G, Bruley des Varannes S, Scarpignato C, *et al.* Reflux related symptoms in patients with normal oesophageal exposure to acid. *Gut* 1995;37:457-64.
- 11 Trimble KC, Douglas S, Pryde A, *et al.* Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. *Dig Dis* 1995;40:1098-104.
- 12 Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? *Am J Gastroenterol* 2002;97:1901-9.
- 13 Fass R, Shapiro M, Dekel R, *et al.* Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? *Aliment Pharmacol Ther* 2005;22:79-94.

- 14 Frazzoni M, de Michell E, Zentilin P, Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. *Aliment Pharmacol Ther* 2004;20:81-8.
- 15 Fry LC, Monkemuller K, Malfertheiner P. Functional heartburn, non-erosive reflux disease, and reflux esophagitis are all distinct conditions - a debate: con. *Curr Treat Options Gastroenterol* 2007;10:305-11.
- 16 Hershcovici T, Zimmerman J. Functional heartburn vs non-erosive reflux disease: similarities and differences. *Aliment Pharmacol Ther* 2008;27:1103-9.
- 17 Fass R. Functional heartburn: what it is and how to treat it. *Gastrointest Endosc Clin North Am* 2009;19:23-33.
- 18 Sacher-Huvelin S, Gournay J, Amouretti M, *et al.* Acid sensitive esophagus: natural history and quality of life of patients with acid hypersensitive esophagus syndrome. Comparison with classical gastro-esophageal reflux disease. *Gastroenterol Clin Biol* 2000;24:911-16.
- 19 Watson RGP, Tham TCK, Johnston BT, *et al.* Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the “sensitive” esophagus. *Gut* 1997;40:587-90.
- 20 Numans ME, Lau J, de Wit NJ, *et al.* Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. *Ann Intern Med* 2004;140:518-27.
- 21 Bruley des Varannes S, Sacher-Huvelin S, Vavasseur F, *et al.* Rabeprazole test for the diagnosis of gastro-esophageal reflux disease: results of a study in a primary care setting. *World J Gastroenterol* 2006;28:2569-73.
- 22 Meineche-Schmidt V, Christensen E, Bytzer P. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study. *Aliment Pharmacol Ther* 2011;33:41-9.
- 23 Savarino E, Zentilin P, Tutuian R, *et al.* The role of nonacid reflux in NERD: lessons learned from impedance pH monitoring in 150 patients off therapy. *Am J Gastroenterol* 2008;103:2685-93.
- 24 Savarino E, Marabotto E, Zentilinn P, *et al.* The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. *Dig Liver Dis* 2011;43(7):542-7.
- 25 Savarino E, Pohl D, Zentilin P, *et al.* Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. *Gut* 2009;58:1185-91.
- 26 Hershcovici T, Fass R. GERD: are functional heartburn and functional dyspepsia one disorder? *Nat Rev Gastroenterol Hepatol* 2010;7:71-2.
- 27 Xiao YL, Peng S, Tao J. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. *Am J Gastroenterol* 2010;105:2626-31.
- 28 Lee KJ, Kwon HC, Cheong JY, *et al.* Demographic, clinical and psychological characteristics of the heartburn groups classified using the Rome III criteria

- and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group. *Digestion* 2009;79:131-6.
- 29 Kaji M, Fujiwara Y, Shiba M. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. *J Gastroenterol Hepatol* 2010;25:1151-6.
- 30 Martinez SD, Malagon IB, Garewal HS, *et al.* Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. *Aliment Pharmacol Ther* 2003;17:537-45.
- 31 Weusten BLAM, Roelofs JMM, Akkermans LM, *et al.* The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. *Gastroenterology* 1994;107:1741-5.
- 32 Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. *Gut* 2002;51:885-92.
- 33 Miwa H, Kondo T, Oshima T, *et al.* Esophageal sensation and esophageal hypersensitivity - overview from bench to bedside. *J Neurogastroenterol Motil* 2010;16:353-62.
- 34 Meyer JH, Lembo A, Elashoff JD, *et al.* Duodenal fat intensifies the perception of heartburn. *Gut* 2001;40:624-8.
- 35 Yang M, Li ZS, Xu XR. Characterization of cortical potentials evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn. *Neurogastroenterol Motil* 2006;18:292-9.
- 36 Kern MK, Birn RM, Jaradeh S, *et al.* Identification and characterization of cerebral cortical response to esophageal mucosal acid exposure and distention. *Gastroenterology* 1998;115:1353-62.
- 37 Kern M, Hofmann C, Hyde J, *et al.* Characterization of the cerebral cortical representation of heartburn in GERD patients. *Am J Physiol Gastrointest Liver Physiol* 2004;286:G174-81.
- 38 Yang M, Li ZS, Chen DF, *et al.* Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. *Clin J Pain* 2010;26:326-31.
- 39 Vela MF, Craft BMM, Sharma N, *et al.* Refractory heartburn: comparison of intercellular space diameter in documented GERD vs functional heartburn. *Am J Gastroenterol* 2011;106:844-50.
- 40 Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. *Am J Physiol Gastrointest Liver Physiol* 2001;281:G743-G751.
- 41 Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. *Gastroenterology* 2005;128:771-8.
- 42 Bradley LA, Richter JE, Pulliam TJ, *et al.* The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. *Am J Gastroenterol* 1993;88:11-19.
- 43 Naliboff BD, Mayer M, Fass R, *et al.* The effect of life stress on symptoms of heartburn. *Psychosom Med* 2004;66:426-34.



- 44 Johnston BT, Lewis SA, Collins JS, *et al.* Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. *Scand J Gastroenterol* 1995;30:1-5.
- 45 Shapiro M, Green C, Bautista JM. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. *Am J Gastroenterol* 2006;10:1084-91.
- 46 Schey R, Dickman R, Parthasarathy S, *et al.* Sleep deprivation is hyperalgesia in patients with gastroesophageal reflux disease. *Gastroenterology* 2007;133:1787-95.
- 47 Prakash C, Clouse RE. Value of extended recording time with a wireless esophageal pH system in patients with gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2005;3:329-34.
- 48 Lee YC, Wang HP, Chiu HM, *et al.* Patients with functional heartburn are more likely to report retrosternal discomfort during wireless pH monitoring. *Gastrointest Endosc* 2005;62:834-41.
- 49 Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. *Gut* 2009;58:295-309.
- 50 Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. *Best Pract Res Clin Gastroenterol* 2010;24:923-36.
- 51 Miwa H, Inoue K, Ashida K. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with nonerosive reflux disease - a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2011;33:323-32.
- 52 Gonlachanvit S. Are rice and spicy diet good for functional gastrointestinal disorders? *J Neurogastroenterol Motil* 2010;16:131-8.
- 53 Shapiro M, Green C, Bautista JM, *et al.* Assessment of dietary nutrients that influence perception of intra-oesophageal acid reflux events in patients with gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2007;25:93-101.
- 54 Siddiqui A, Rodriguez-Stanley S, Zubaidi S. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. *Dig Dis Sci* 2005;50:81-5.
- 55 McDonald-Haile J, Bradley LA, Bailey MA, *et al.* Relaxation training reduces symptom reports and acid exposure in patients with gastroesophageal reflux disease. *Gastroenterology* 1994;107:61-9.
- 56 Miner PB Jr, Rodriguez-Stanley S, Proskin HM, *et al.* Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. *Curr Med Res Opin* 2008;24:2159-72.
- 57 Krarup AL, Ny L, Astrand M. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. *Aliment Pharmacol Ther* 2011;33:1113-22.
- 58 Khajanchee YS, Hong D, Hansen PD, *et al.* Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. *Am J Surg* 2004;187:599-603.

- 59 Thompson SK, Cai W, Jamieson GG. Recurrent symptoms after fundoplication with a negative pH study - recurrent reflux or functional heartburn? *J Gastrointest Surg* 2009;13:54-60.
- 60 Galmiche JP, Bruley des Varannes S. Endoluminal therapies for gastro-oesophageal reflux disease. *Lancet* 2003;361:1119-21.
- 61 Arts J, Tack J, Galmiche JP. Endoscopic antireflux procedures. *Gut* 2004;53:1207-14.
- 62 Boyd C, Abraham S, Kellow J. Appearance and disappearance of functional gastrointestinal disorders in patients with eating disorders. *Neurogastroenterol Motil* 2010;22:1279-83.

## Literatura

- 1 Eslick GD. Epidemiology. In: Fass R, Eslick GD (eds) *Non cardiac chest pain, a growing medical problem*. San Diego, CA: Plural Publishing, 2007: pp.1-12.
- 2 Rey E, Moreno Elola-Elaso C, Rodriguez Artalejo F, *et al.* Prevalence of atypical symptoms and their association with typical symptoms of gastroesophageal reflux in Spain. *Eur J Gastroenterol* 2006;18(9):969-75.
- 3 Agreus L, Svardstudd K, Nyren O, *et al.* The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. *Scand J Gastroenterol* 1994;29:102-9.
- 4 Locke GR 3rd, Talley NJ, Fett SL, *et al.* Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. *Gastroenterology* 1997;112(5):1448-56.
- 5 Pope JH, Aufderheide TP, Ruthazer R, *et al.* Missed diagnoses of acute cardiac ischemia in the emergency department. *N Engl J Med* 2000;342(16):1163-70.
- 6 Phan A, Shufelt C, Bairey Mertz CN. Persistent chest pain and no obstructive coronary disease. *JAMA* 2009;301(14):1468-74.
- 7 Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting - a population-based study. *Aliment Pharmacol Ther* 2003;17:1115-24.
- 8 Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. *National Health Stat Rep* 2010;26:1-32.
- 9 [www.healthcaretrendsnewsletter.com/2010/01/ten-most-frequent-outpatient-diagnoses-and-average-cost/](http://www.healthcaretrendsnewsletter.com/2010/01/ten-most-frequent-outpatient-diagnoses-and-average-cost/)
- 10 Eslick GD, Talley NJ. Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities. *Aliment Pharmacol Ther* 2004;20(8):909-15.
- 11 Lam HG, Dekker W, Kan G, *et al.* Acute noncardiac chest pain in a coronary care unit. Evaluation by 24-hour pressure and pH recording of the esophagus. *Gastroenterology* 1992;102(2):453-60.
- 12 Achem SR. Noncardiac chest pain - treatment approaches. *Gastroenterol Clin North Am* 2008;37:859-78.
- 13 Wise JL, Locke GR, Zinsmeister AR, *et al.* Risk factors for non-cardiac chest pain in the community. *Aliment Pharmacol Ther* 2005;22:1023-31.
- 14 Hewson EG, Sinclair JW, Dalton CB, *et al.* Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. *Am J Med* 1991;90(5):576-83.
- 15 Beedassy A, Katz PO, Gruber A, *et al.* Prior sensitization of esophageal mucosa by acid reflux predisposes to a reflux-induced chest pain. *J Clin Gastroenterol* 2000; 31(2):121-4.

- 16 Lacima G, Grande L, Pera M, *et al.* Utility of ambulatory 24-hour esophageal pH and motility monitoring in noncardiac chest pain: report of 90 patients and review of the literature. *Dig Dis Sci* 2003;48:952-61.
- 17 Dekel R, Martinez-Hawthorne SD, Guillen J, *et al.* Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. *J Clin Gastroenterol* 2004;38(1):24-9.
- 18 Williams JE, Sontag SJ, Schnell T, *et al.* Non-cardiac chest pain: the long term natural history and comparison with gastroesophageal reflux disease. *Am J Gastroenterol* 2009;104:2145-52.
- 19 Dickman R, Mattek N, Holub J, *et al.* Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. *Am J Gastroenterol* 2007;102:1173-9.
- 20 Smith JL, Opekun AR, Larkai E, *et al.* Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. *Gastroenterology*.1989;96(3):683-9.
- 21 Richter JE, Hewson EG, Sinclair JW, *et al.* Acid perfusion test and 24-hour esophageal pH monitoring with symptom index. Comparison of tests for esophageal acid sensitivity. *Dig Dis Sci* 1991;36(5):565-71.
- 22 Lam HG, Breumelhof R, van Berge Henegouwen GP, *et al.* Temporal relationships between episodes of non-cardiac chest pain and abnormal oesophageal function. *Gut* 1994;35(6):733-6.
- 23 Katz PO, Dalton CB, Richter JE, *et al.* Esophageal testing of patients with non-cardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. *Ann Intern Med* 1987;106(4):593-7.
- 24 Behar J, Biancani P, Sheahan DG. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. *Gastroenterology* 1976;71(1):9-15.
- 25 Cremonini F, Wise J, Moayyedi P, *et al.* Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. *Am J Gastroenterol* 2005;100(6):1226-32.
- 26 Wang WH, Huang JQ, Zheng GF, *et al.* Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? A meta-analysis. *Arch Intern Med* 2005;165(11):1222-8.
- 27 Orlando RC. Esophageal perception and noncardiac chest pain. *Gastroenterol Clin North Am* 2004;33:25-33.
- 28 Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. *Gastroenterology* 2005;128:771-8.
- 29 Barlow JD, Gregersen H, Thompson G. Identification of the biomechanical factors associated with the perception of distension in the human esophagus. *Am J Physiol Gastrointest Liver Physiol* 2002;282:G683-9.
- 30 Richter JE, Barish CF, Castell DO. Abnormal sensory perception in patients with esophageal chest pain. *Gastroenterology* 1986;91(4):845-52.
- 31 Hobson AR, Furlong PL, Sarkar S, *et al.* Neurophysiologic assessment of esophageal sensory processing in noncardiac chest pain. *Gastroenterology* 2006;130:80-8.

- 32 Hollerbach S, Bulat R, May A, *et al.* Abnormal cerebral processing of oesophageal stimuli in patients with noncardiac chest pain (NCCP). *Neurogastroenterol Motil* 2000;12(6):555-65.
- 33 Hu WH, Martin CJ, Talley NJ. Intraesophageal acid perfusion sensitizes the esophagus to mechanical distension: a Barostat study. *Am J Gastroenterol* 2000;95(9): 2189-94.
- 34 Sarkar S, Aziz Q, Woolf CJ, *et al.* Contribution of central sensitisation to the development of non-cardiac chest pain. *Lancet* 2000;356:1154-9.
- 35 Sarkar S, Thompson DG, Woolf CJ, *et al.* Patients with chest pain and occult gastro-esophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression. *Am J Gastroenterol* 2004;99(10):1998-2006.
- 36 Balaban DH, Yamamoto Y, Liu J, *et al.* Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. *Gastroenterology* 1999;116(1):29-37.
- 37 Liuzzo JP, Ambrose JA. Chest pain from gastroesophageal reflux disease in patients with coronary artery disease. *Cardiol Rev* 2005;13:167-73.
- 38 Mehta AJ, Caestecker JS, Camm AJ, *et al.* Gastro-esophageal reflux in patients with coronary artery disease: how common is it and does it matter? *Eur J Gastroenterol Hepatol* 1996;8:973-8.
- 39 Schultz T, Mannheimer C, Dellborg M, *et al.* High prevalence of gastroesophageal reflux in patients with clinical unstable angina and known coronary artery disease. *Acute Cardiac Care* 2008;10:37-42.
- 40 Liuzzo JP, Ambrose JA, Diggs P. Proton pump inhibitor use by coronary artery disease patients is associated with fewer chest pain episodes, emergency department visits and hospitalizations. *Aliment Pharmacol Ther* 2005;22:95-100.
- 41 Budzynski J, Klopocka M, Pulkowski G, *et al.* The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease - a randomised, double-blind, placebo controlled, crossover trial. *Int J Cardiol* 2008;127(2):233-9.
- 42 Froment R. [Intricated coronary angina; clinical and experimental data]. *Brux Med* 1955;35(49):2429-42.
- 43 Smith KS, Papp C. Episodic, postural, and linked angina. *BMJ* 1962;2(5317):1425-30.
- 44 Mellow M, Simpson AG, Watt L, *et al.* Esophageal acid perfusion in coronary artery disease: induction of myocardial ischemia. *Gastroenterology* 1983;85:306-12.
- 45 Chauhan A, Petch MC, Schofield PM. Effect of esophageal acid instillation on coronary blood flow. *Lancet* 1993;341:1309-10.
- 46 Chauhan A, Petch MC, Schofield PM. Cardio-esophageal reflex in humans as a mechanism for 'linked angina'. *Eur Heart J* 1996;17:407-13.
- 47 Voskuil JH, Cramer MJ, Breumelhof R, *et al.* Prevalence of esophageal disorders in patients with chest pain newly referred to the cardiologist. *Chest* 1996;109: 1210-14.

- 48 Karcz A, Korn R, Burke MC, *et al.* Malpractice claims against emergency physicians in Massachusetts: 1975-1993. *Am J Emerg Med* 1996;14(4):341-5.
- 49 Mousavi S, Tosi J, Eskandarian R, *et al.* Role of clinical presentation in diagnosing reflux-related non-cardiac chest pain. *J Gastroenterol Hepatol* 2007;22:218-21.
- 50 Richter JE, Boeckxstaens GE. Management of achalasia: surgery or pneumatic dilation. *Gut* 2011;60(6):869-76.
- 51 Lacy BE, Weiser K, Chertoff J, *et al.* The diagnosis of gastroesophageal reflux disease. *Am J Med* 2010;123(7):583-92.
- 52 Garda-Compean D, Gonzalez MV, Galindo G, *et al.* Prevalence of gastroesophageal reflux disease in patients with extraesophageal symptoms referred from otolaryngology, allergy, and cardiology practices: a prospective study. *Dig Dis* 2000;18(3):178-82.
- 53 Battaglia E, Bassotti G, Buonafede G, *et al.* Noncardiac chest pain of esophageal origin in patients with and without coronary artery disease. *Hepatogastroenterology* 2005;52(63):792-5.
- 54 Gibbs JF, Rajput A, Chadha KS, *et al.* The changing profile of esophageal cancer pre-sentation and its implication for diagnosis. *JAMA* 2007;99(6):620-6.
- 55 Achem SR, Almansa C, Murli K, *et al.* Esophageal eosinophilic infiltration in patients with non cardiac chest pain. *Aliment Pharm Ther* 2011;33(11):1194-201.
- 56 Dekel R, Pearson T, Wendel C, *et al.* Assesment of esophageal motor function in patients with dyspepsia or chest pain - the Clinical Outcomes Research Initiative experience. *Aliment Pharmacol Ther* 2003;18(11-12):1083-9.
- 57 Achem SR, Kolts BE, MacMath T, *et al.* Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. *Dig Dis Sci* 1997;42(10):2138-45.
- 58 Achem SR. Noncardiac chest pain - treatment approaches. *Gastroenterol Clin North Am* 2008;37:859-78.
- 59 Achem SR. Treatment of non-cardiac chest pain. *Dis Mon* 2008;54(9):642-70.
- 60 Gerson LB, Achem SR. Prevalence of pathologic reflux disease in patients with spastic motility disorders. *Gastroenterology* 2011;140(5)(Suppl 1):S-232.
- 61 Almansa C, Heckman MG, Devault KR, *et al.* Esophageal spasm: demographic, clinical, radiographic, and manometric features in 108 patients. *Dis Esophagus* 2012;25(3):214-21.
- 62 Fass R, Fennerty MB, Ofman JJ, *et al.* The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. *Gastroenterology* 1998;115(1):42-9.
- 63 Young MA, Sanowski R, Talbert G, *et al.* Omeprazole administration as a test for gas-troesophageal reflux. *Gastroenterology* 1992;102:192.
- 64 Squillace SJ, Young MF, Sanowski RA. Single dose omeprazole as a test for non cardiac chest pain. *Gastroenterology* 1993;104:A197.
- 65 Kim JH, Sinn DH, Son HJ, *et al.* Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. *J Gastroenterol Hepatol* 2009;24(9): 1504-9.

- 66 Giannini EG, Zentilin P, Dulbecco P, *et al.* Management strategy for patients with gas-troesophageal reflux disease: a comparison between empirical treatment with esome-prazole and endoscopy-oriented treatment. *Am J Gastroenterol* 2008;103(2):267-75.
- 67 Faybush EM, Fass R. Gastroesophageal reflux disease in noncardiac chest pain. *Gastroenterol Clin North Am* 2004;33:41-54.
- 68 Pandolfino JE, Vela MF. Esophageal-reflux monitoring. *Gastrointest Endosc* 2009;69(4):917-30.
- 69 Fass R. Proton pump inhibitor failure - what are the therapeutic options? *Am J Gastroenterol* 2009;104(Suppl 2):S33-8.
- 70 Wiener GJ, Richter JE, Copper JB, *et al.* The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. *Am J Gastroenterol* 1988;83:358-61.
- 71 Breumelhof R, Smout APJM. The symptom sensitivity index: a valuable additional parameter in 24-h esophageal pH recording. *Am J Gastroenterol* 1991;86:160-4.
- 72 Weusten BL, Rolfs JMM, Akkermans LMA, *et al.* The symptom association probability: an improved method for symptom analysis of 24-h esophageal pH data. *Gastroenterology* 1994;107:1741-5.
- 73 Ghillebert G, Janssens J, Vantrappen G, *et al.* Ambulatory 24-h intraesophageal pH and pressure recordings vs provocation test in the diagnosis of chest pain of esophageal origin. *Gut* 1990;31:738-44.
- 74 Hirano I, Richter J E. ACG practice guidelines; esophageal reflux testing. *Am J Gastroenterol* 2007;102:668-85.
- 75 Taghavi SA, Ghasedi M, Saberi-Firoozi M, *et al.* Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. *Gut* 2005;54(8):1067-71.
- 76 Kushnir VM, Sayuk GS, Gyawali CP. Abnormal GERD parameters on ambulatory pH monitoring predicts therapeutic success in noncardiac chest pain. *Am J Gastroenterol* 2010;105:1032-8.
- 77 Prakash C, Clouse RE. Wireless pH monitoring in patients with non-cardiac chest pain. *Am J Gastroenterol* 2006;101:446-52.
- 78 Sweis R, Fox M, Anggiansah R, *et al.* Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies. *Aliment Pharmacol Ther* 2009;29(6):669-76.
- 79 Kim BJ, Choi SC, Kim JJ, *et al.* Pathological bolus exposure plays a significant role in eliciting non-cardiac chest pain. *J Gastroenterol Hepatol* 2010;25(12):1855-60.
- 80 Mainie I, Tutuian R, Shay S, *et al.* Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006;55:1398-402.
- 81 Pandak WM, Arezo S, Everett S, *et al.* Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. *J Clin Gastroenterol* 2002;35(4):307-14.

- 82 Bautista J, Fullerton H, Briseno M, *et al.* The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - a randomized, double-blind, placebo-controlled, crossover trial. *Aliment Pharmacol Ther* 2004;19(10):1123-30.
- 83 Dickman R, Emmons S, Cui H, *et al.* The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. *Aliment Pharmacol Ther* 2005;22(6):547-55.
- 84 Chambers J, Cooke R, Anggiansah A, *et al.* Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. *Int J Cardiol* 1998;65(1):51-5.
- 85 Xia HH, Lai KC, Lam SK, *et al.* Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. *Aliment Pharmacol Ther* 2003;17(3):369-77.
- 86 Achem SR, Kolts BE, Wears R, *et al.* Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. *Am J Gastroenterol* 1993;88(2):187-92.
- 87 Oranu AC, Vaezi MF. Noncardiac chest pain: gastroesophageal reflux disease. *Med Clin North Am* 2010;94(2):233-42.
- 88 Patti MG, Molena D, Fisichella PM, *et al.* Gastroesophageal reflux disease (GERD) and chest pain. Results of laparoscopic antireflux surgery. *Surg Endosc* 2002;16(4):563-6.
- 89 So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastro-esophageal reflux treated by laparoscopic fundoplication. *Surgery* 1998;124(1):28-32.
- 90 Chen RYM, Thomas RJS. Results of laparoscopic fundoplication where atypical symptoms coexist with oesophageal reflux. *Aust NZ J Surg* 2000;70:840-2.
- 91 Farrell TM, Richardson WS, Trus TL, *et al.* Response of atypical symptoms of gastro-esophageal reflux to antireflux surgery. *Br J Surg* 2001;88(12):1649-52.
- 92 Rakita S, Valladolid D, Thomas A, *et al.* Laparoscopic nissen fundoplication offers high patient satisfaction with relief of extraesophageal symptoms of gastroesophageal reflux disease. *Am Surg* 2006;72(3):207-12.
- 93 Eslick GD, Talley NJ. Natural history and predictors of outcome for non-cardiac chest pain: a prospective 4-year cohort study. *Neurogastroenterol Motil* 2008;20(9):989-97.
- 94 Wilhelmsen L, Rosengren A, Hagman M, Lappas G. “Nonspecific” chest pain associated with high long-term mortality: results from the primary prevention study in Goteborg, Sweden. *Clin Cardiol* 1998;21(7):477-82.



## Literatura

- 1 Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. *Clin Gastroenterol Hepatol* 2003;1(5):333-44.
- 2 Koufman JA Wiener GJ, Wallace CW, *et al.* Reflux laryngitis and its sequelae: the diagnostic role of ambulatory 24-h pH monitoring. *J Voice* 1988;2:78-9.
- 3 Gaynor EB. Otolaryngologic manifestations of gastroesophageal reflux. *Am J Gastroenterol* 1991;86(7):801-8.
- 4 Graser A. Gastroesophageal reflux and laryngeal symptoms. *Aliment Pharmacol Ther* 1994;8:265-72.
- 5 Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. *J Voice* 1996;10(3):215-16.
- 6 Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. *Laryngoscope* 1991;101(4 Pt 2 Suppl 53):1-78.
- 7 Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. *Gastroenterol Clin North Am* 1996;25(1):75-102.
- 8 Toohill RJ, Kuhn JC. Role of refluxed acid in pathogenesis of laryngeal disorders. *Am J Med* 1997;103(5A):100S-6S.
- 9 Ward PH Hanson DG. Reflux as an etiological factor of carcinoma of the laryngopharynx. *Laryngoscope* 1998;98:1195-9.
- 10 Freije JE, Beatty TW, Campbell BH, Woodson BT, Schultz CJ, Toohill RJ. Carcinoma of the larynx in patients with gastroesophageal reflux. *Am J Otolaryngol* 1996;17(6):386-90.
- 11 Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma? *Otolaryngol Head Neck Surg* 1988;99(4):370-3.
- 12 Vaezi MF, Qadeer MA, Lopez R, Colabianchi N. Laryngeal cancer and gastroesophageal reflux disease: a case-control study. *Am J Med* 2006;119(9):768-76.
- 13 Qadeer MA, Colabianchi N, Strome M, Vaezi MF. Gastroesophageal reflux and laryngeal cancer: causation or association? A critical review. *Am J Otolaryngol* 2006;27(2):119-28.
- 14 Coffin L. The relationship of upper airway passages to diseases of gastrointestinal tract. *Ann Otol Rhinol Laryngol* 1903;12:521-6.
- 15 Jackson C MS. Contact ulcer of larynx. *Ann Otol Rhinol Laryngol* 1928;37:227-30.
- 16 Cherry J, Margulies SI. Contact ulcer of the larynx. *Laryngoscope* 1968;78(11):1937-40.

- 17 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101(8):1900-20; quiz 1943.
- 18 Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. *Gastroenterology* 2008;135(4):1392-413.
- 19 Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997;112(5):1448-56.
- 20 El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. *Gastroenterology* 1997; 113(3):755-60.
- 21 Sontag SJ, O'Connell S, Khandelwal S, *et al.* Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. *Am J Gastroenterol* 2003;98(5):987-99.
- 22 Kahrilas PJ, Shaheen NJ, Vaezi MF, *et al.* American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology* 2008;135(4): 1383-91.
- 23 Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. *Am J Gastroenterol* 2003;98(7):1487-93.
- 24 Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. *Otolaryngol Head Neck Surg* 2002;127(1):32-5.
- 25 Hanson DG, Jiang JJ. Diagnosis and management of chronic laryngitis associated with reflux. *Am J Med* 2000;108(Suppl 4a):112S-9S.
- 26 Loughlin CJ, Koufman JA, Averill DB, *et al.* Acid-induced laryngospasm in a canine model. *Laryngoscope* 1996;106(12 Pt 1):1506-9.
- 27 Adhami T, Goldblum JR, Richter JE, Vaezi MF. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. *Am J Gastroenterol* 2004;99(11):2098-106.
- 28 Vaezi MF. Laryngitis: from the gastroenterologist's point of view. In: Vaezi MF (ed) *Extraesophageal reflux*. San Diego, CA: Plural Publishing, 2009: pp. 37-47.
- 29 Sidhu H, Shaker R, Hogan WJ. Gastroesophageal reflux laryngitis. In: Castell DO, Richter JE (eds) *The esophagus*, 4th edn. Philadelphia: Lippincott, Williams and Wilkins, 2003: pp. 518-29.
- 30 Hogan WJ, Shaker R. Supraesophageal complications of gastroesophageal reflux. *Dis Mon* 2000;46(3):193-232.
- 31 Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). *J Voice* 2002;16(2):274-7.
- 32 Park KH, Choi SM, Kwon SU, Yoon SW, Kim SU. Diagnosis of laryngopharyngeal reflux among globus patients. *Otolaryngol Head Neck Surg* 2006;134(1):81-5.

- 33 Sataloff RT. *Professional voice: the science and art of clinical care*, 2nd edn. San Diego, CA: Singular Publishing Group, 1997.
- 34 Ford CN. Evaluation and management of laryngopharyngeal reflux. *JAMA* 2005; 294(12):1534–40.
- 35 Weinberger PM, Postma GN. Laryngopharyngeal reflux from the otolaryngologist 's perspective. In: Vaezi MF (ed) *Extraesophageal reflux*. San Diego, CA: Plural Publishing, 2009: pp. 49-66.
- 36 Axford SE, Sharp N, Ross PE, *et al.* Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies. *Ann Otol Rhinol Laryngol* 2001;110(12): 1099-108.
- 37 Ahmed TF, Khandwala F, Abelson TI, *et al.* Chronic laryngitis associated with gastro-esophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians. *Am J Gastroenterol* 2006;101(3):470-8.
- 38 Book DT, Rhee JS, Toohill RJ, Smith TL. Perspectives in laryngopharyngeal reflux: an international survey. *Laryngoscope* 2002;112(8 Pt 1):1399-406.
- 39 Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypo- pharynx findings associated with gastroesophageal reflux in normal volunteers. *J Voice* 2002;16(4):564-79.
- 40 Vaezi MF, Ours TM, Hicks DM, *et al.* Laryngoscopic signs of gastroesophageal reflux disease: science or fiction? *Am J Gastroenterol* 1999;94:2601.
- 41 Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). *Laryngoscope* 2001;111(8):1313-17.
- 42 Mesallam TA, Stemple JC, Sobeih TM, Elluru RG. Reflux symptom index versus reflux finding score. *Ann Otol Rhinol Laryngol* 2007;116(6):436-40.
- 43 Milstein CF, Charbel S, Hicks DM, Abelson TI, Richter JE, Vaezi MF. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). *Laryngoscope* 2005; 115(12):2256-61.
- 44 Park W, Hicks DM, Khandwala F, *et al.* Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. *Laryngoscope* 2005;115(7):1230-8.
- 45 Merati AL, Lim HJ, Ulualp SO, Toohill RJ. Meta-analysis of upper probe measurements in normal subjects and patients with laryngopharyngeal reflux. *Ann Otol Rhinol Laryngol* 2005;114(3):177-82.
- 46 Ahmed T, Vaezi MF. The role of pH monitoring in extraesophageal gastroesophageal reflux disease. *Gastrointest Endosc Clin North Am* 2005;15(2):319-31.
- 47 Jacob P, Kahrilas PJ, Herzog G. Proximal esophageal pH-metry in patients with 'reflux laryngitis'. *Gastroenterology* 1991;100(2):305-10.
- 48 Oelschlager BK, Eubanks TR, Maronian N, *et al.* Laryngoscopy and pharyngeal pH are complementary in the diagnosis of gastroesophageal-laryngeal reflux. *J Gastrointest Surg* 2002;6(2):189-94.
- 49 Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. *Am J Gastroenterol* 2007;102(3):668-85.

- 50 Wo JM, Jabbar A, Winstead W, Goudy S, Cacchione R, Allen JW. Hypopharyngeal pH monitoring artifact in detection of laryngopharyngeal reflux. *Dig Dis Sci* 2002;47(11):2579-85.
- 51 Noordzij JP, Khidr A, Desper E, Meek RB, Reibel JF, Levine PA. Correlation of pH probe-measured laryngopharyngeal reflux with symptoms and signs of reflux laryngitis. *Laryngoscope* 2002;112(12):2192-5.
- 52 Ulualp SO, Toohill RJ, Shaker R. Outcomes of acid suppressive therapy in patients with posterior laryngitis. *Otolaryngol Head Neck Surg* 2001;124(1):16-22.
- 53 Eubanks TR, Omelanczuk PE, Maronian N, Hillel A, Pope CE 2nd, Pellegrini CA. Pharyngeal pH monitoring in 222 patients with suspected laryngeal reflux. *J Gastrointest Surg* 2001;5(2):183-90; discussion 190-1.
- 54 Maldonado A, Diederich L, Castell DO, Gideon RM, Katz PO. Laryngopharyngeal reflux identified using a new catheter design: defining normal values and excluding artifacts. *Laryngoscope* 2003;113(2):349-55.
- 55 Shaker R, Bardan E, Gu C, Kern M, Torrico L, Toohill R. Intrapharyngeal distribution of gastric acid refluxate. *Laryngoscope* 2003;113(7):1182-91.
- 56 Belafsky PC, Postma GN, Daniel E, Koufman JA. Transnasal esophagoscopy. *Otolaryngol Head Neck Surg* 2001;125(6):588-9.
- 57 Vaezi MF, Richter JE, Stasney CR, *et al.* Treatment of chronic posterior laryngitis with esomeprazole. *Laryngoscope* 2006;116(2):254-60.
- 58 Vaezi MF. Reflux-induced laryngitis (laryngopharyngeal reflux). *Curr Treat Options Gastroenterol* 2006;9(1):69-74.
- 59 Sifrim D, Blondeau K. Technology insight: the role of impedance testing for esophageal disorders. *Nat Clin Pract Gastroenterol Hepatol* 2006;3(4):210-19.
- 60 Mainie I, Tutuian R, Shay S, *et al.* Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006;55(10):1398-402.
- 61 Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intra-luminal impedance-pH monitoring to select patients with persistent gastro-esophageal reflux for laparoscopic Nissen fundoplication. *Br J Surg* 2006;93(12):1483-7.
- 62 Shay S, Tutuian R, Sifrim D, *et al.* Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. *Am J Gastroenterol* 2004;99(6):1037-43.
- 63 Vaezi MF, Hicks DM, Ours TM, Richter JE. ENT manifestation of GERD: a large prospective study assessing treatment outcome and predictors of response. *Gastroenterology* 2001;120:A636.
- 64 Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastro-esophageal reflux disease, on and off therapy. *Clin Gastroenterol Hepatol* 2009;7(7):743-8.
- 65 Fletcher KC GM, Slaughter JC, Garrett CG, Vaezi MF. Significance and degree of reflux in patients with primary extraesophageal symptoms. *Laryngoscope* 2011; 121(12):2561-5.

- 66 Sun G, Muddana S, Slaughter JC, *et al.* A new pH catheter for laryngopharyngeal reflux: normal values. *Laryngoscope* 2009;119(8):1639-43.
- 67 Wiener GJ, Tsukashima R, Kelly C, *et al.* Oropharyngeal pH monitoring for the detection of liquid and aerosolized supraesophageal gastric reflux. *J Voice* 2009;23(4): 498-504.
- 68 Reichel O, Keller J, Rasp G, Hagedorn H, Berghaus A. Efficacy of once-daily esome- prazole treatment in patients with laryngopharyngeal reflux evaluated by 24-hour pH monitoring. *Otolaryngol Head Neck Surg* 2007;136(2):205-10.
- 69 Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux? A critical review of the literature. *Chest* 1998;114(1):275-83.
- 70 Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. *Am J Gastroenterol* 2005;100(2):283-9.
- 71 Havas T, Huang S, Levy M, *et al.* Posterior pharyngolaryngitis: double-blind randomised placebo-controlled trial of proton pump inhibitor therapy. *Aust J Otolaryngol* 1999;3:243.
- 72 Wo JM, Koopman J, Harrell SP, Parker K, Winstead W, Lentsch E. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. *Am J Gastroenterol* 2006;101(9):1972-8; quiz 2169.
- 73 Steward DL, Wilson KM, Kelly DH, *et al.* Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. *Otolaryngol Head Neck Surg* 2004;131(4):342-50.
- 74 Qadeer MA, Phillips CO, Lopez AR, *et al.* Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2006;101(11):2646-54.
- 75 Reichel O, Dressel H, Wiederanders K, Issing WJ. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. *Otolaryngol Head Neck Surg* 2008;139(3):414-20.
- 76 El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. *Am J Gastroenterol* 2001;96(4):979-83.
- 77 Oridate N, Takeda H, Yamamoto J, *et al.* *Helicobacter pylori* seropositivity predicts outcomes of acid suppression therapy for laryngopharyngeal reflux symptoms. *Laryngoscope* 2006;116(4):547-53.
- 78 Vaezi MF, Hagaman DD, Slaughter JC, *et al.* Proton pump inhibitor therapy improves symptoms in postnasal drainage. *Gastroenterology* 2010;139(6):1887-93.
- 79 Ulualp SO, Toohill RJ. Laryngopharyngeal reflux: state of the art diagnosis and treatment. *Otolaryngol Clin North Am* 2000;33(4):785-802.
- 80 Belafsky PC, Postma GN, Koufman JA. Laryngopharyngeal reflux symptoms improve before changes in physical findings. *Laryngoscope* 2001;111(6):979-81.
- 81 Bough ID Jr, Sataloff RT, Castell DO, Hills JR, Gideon RM, Spiegel JR. Gastroesophageal reflux laryngitis resistant to omeprazole therapy. *J Voice* 1995;9(2):205-11.

- 82 Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. *Aliment Pharmacol Ther* 1992; 6(1):103-11.
- 83 Kahrilas PJ, Falk GW, Johnson DA, *et al.* Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. *Aliment Pharmacol Ther* 2000;14(10):1249-58.
- 84 Shaw GY, Searl JP. Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole. *South Med J* 1997;90(11):1115-22.
- 85 Hunter JG, Trus TL, Branum GD, Waring JP, Wood WC. A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. *Ann Surg* 1996;223(6):673-85; discussion 685-7.
- 86 Dallemagne B, Weerts JM, Jeahes C, Markiewicz S. Results of laparoscopic Nissen fundoplication. *Hepatogastroenterology* 1998;45(23):1338-43.
- 87 Koufman JA, Belafsky PC, Bach KK, Daniel E, Postma GN. Prevalence of esophagitis in patients with pH-documented laryngopharyngeal reflux. *Laryngoscope* 2002; 112(9):1606-9.
- 88 Halum SL, Postma GN, Bates DD, Koufman JA. Incongruence between histologic and endoscopic diagnoses of Barrett's esophagus using transnasal esophagoscopy. *Laryngoscope* 2006;116(2):303-6.
- 89 Bjornsson E, Abrahamsson H, Simren M, *et al.* Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. *Aliment Pharmacol Ther* 2006;24(6):945-54.
- 90 Wright RC, Rhodes KP. Improvement of laryngopharyngeal reflux symptoms after laparoscopic Hill repair. *Am J Surg* 2003;185(5):455-61.
- 91 Salminen P, Sala E, Koskenvuo J, Karvonen J, Ovaska J. Reflux laryngitis: a feasible indication for laparoscopic antireflux surgery? *Surg Laparosc Endosc Percutan Tech* 2007;17(2):73-8.
- 92 Swoger J, Ponsky J, Hicks DM, *et al.* Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. *Clin Gastroenterol Hepatol* 2006;4(4):433-41.
- 93 Tutuian R, Mainie I, Agrawal A, Adams D, Castell DO. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. *Chest* 2006;130(2):386-91.
- 94 Ossakow SJ, Elta G, Colturi T, Bogdasarian R, Nostrant T.T. Esophageal reflux and dysmotility as the basis for persistent cervical symptoms. *Ann Otol Rhinol Laryngol* 1987;96(4):387-92.
- 95 Wiener GJ, Koufman JA, Wu WC, Cooper JB, Richter JE, Castell DO. Chronic hoarseness secondary to gastroesophageal reflux disease: documentation with 24-h ambulatory pH monitoring. *Am J Gastroenterol* 1989;84(12):1503-8.
- 96 Wilson JA, White A, von Haacke NP, *et al.* Gastroesophageal reflux and posterior laryngitis. *Ann Otol Rhinol Laryngol* 1989;98(6):405-10.

- 97 Katz PO. Ambulatory esophageal and hypopharyngeal pH monitoring in patients with hoarseness. *Am J Gastroenterol* 1990;85(1):38-40.
- 98 Woo P, Noordzij P, Ross JA. Association of esophageal reflux and globus symptom: comparison of laryngoscopy and 24-hour pH manometry. *Otolaryngol Head Neck Surg* 1996;115(6):502-7.
- 99 Metz DC, Childs ML, Ruiz C, Weinstein GS. Pilot study of the oral omeprazole test for reflux laryngitis. *Otolaryngol Head Neck Surg* 1997;116(1):41-6.
- 100 Vaezi MF, Schroeder PL, Richter JE. Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. *Am J Gastroenterol* 1997;92(5):825-9.
- 101 Chen MY, Ott DJ, Casolo BJ, Moghazy KM, Koufman JA. Correlation of laryngeal and pharyngeal carcinomas and 24-hour pH monitoring of the esophagus and pharynx. *Otolaryngol Head Neck Surg* 1998;119(5):460-2.
- 102 Ulualp SO, Toohill RJ, Hoffmann R, Shaker R. Pharyngeal pH monitoring in patients with posterior laryngitis. *Otolaryngol Head Neck Surg* 1999;120(5):672-7.
- 103 Smit CF, Copper MP, van Leeuwen JA, Schoots IG, Stanojcic LD. Effect of cigarette smoking on gastropharyngeal and gastroesophageal reflux. *Ann Otol Rhinol Laryngol* 2001;110(2):190-3.
- 104 Noordzij JP, Khidr A, Evans BA, *et al.* Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. *Laryngoscope* 2001;111(12):2147-51.
- 105 Eherer AJ, Habermann W, Hammer HF, Kiesler K, Friedrich G, Krejs GJ. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. *Scand J Gastroenterol* 2003;38(5):462-7.

## Literatura

- 1 Richter JE. Review article: extraoesophageal manifestations of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2005;22(Suppl 1):70-80.
- 2 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Group GC. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101(8):1900-20; quiz 43.
- 3 Pratter MR. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. *Chest* 2006;129(1 Suppl):63S-71S.
- 4 Irwin RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. *Chest* 2006;129(1 Suppl):80S-94S.
- 5 Smith J, Woodcock A, Houghton L. New developments in reflux-associated cough. *Lung* 2010;188(Suppl 1):S81-6.
- 6 Marchesani F, Cecarini L, Pela R, Sanguinetti CM. Causes of chronic persistent cough in adult patients: the results of a systematic management protocol. *Monaldi Arch Chest Dis* 1998;53(5):510-14.
- 7 Palombini BC, Villanova CA, Araujo E, *et al.* A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. *Chest* 1999;116(2):279-84.
- 8 Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. *Am Rev Respir Dis* 1981;123(4 Pt 1):413-17.
- 9 Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Am Rev Respir Dis* 1990;141(3):640-7.
- 10 French CL, Irwin RS, Curley FJ, Krikorian CJ. Impact of chronic cough on quality of life. *Arch Intern Med* 1998;158(15):1657-61.
- 11 Ledson MJ, Wilson GE, Tran J, Walshaw MJ. Tracheal microaspiration in adult cystic fibrosis. *J Roy Soc Med* 1998;91(1):10-12.
- 12 Sun G, Muddana S, Slaughter JC, *et al.* A new pH catheter for laryngopharyngeal reflux: normal values. *Laryngoscope* 2009;119(8):1639-43.
- 13 Ahrens P, Noll C, Kitz R, Willigens P, Zielen S, Hofmann D. Lipid-laden alveolar macrophages (LLAM): a useful marker of silent aspiration in children. *Pediatr Pulmonol* 1999;28(2):83-8.
- 14 Parameswaran K, Anvari M, Efthimiadis A, Kamada D, Hargreave FE, Allen CJ. Lipid-laden macrophages in induced sputum are a marker of oropharyngeal reflux and possible gastric aspiration. *Eur Respir J* 2000;16(6):1119-22.
- 15 Koksall D, Ozkan B, Simsek C, Koksall AS, Agagkyran Y, Sa\$maz N. Lipid-laden alveolar macrophage index in sputum is not useful in the differential diagnosis of pulmonary symptoms secondary to gastroesophageal reflux. *Arch Med Res* 2005;36(5):485-9.



- 16 Krishnan U, Mitchell JD, Tobias V, Day AS, Bohane TD. Fat laden macrophages in tracheal aspirates as a marker of reflux aspiration: a negative report. *J Pediatr Gastroenterol Nutr* 2002;35(3):309-13.
- 17 Blondeau K, Mertens V, Vanaudenaerde BA, *et al.* Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. *Eur Respir J* 2008;31(4):707-13.
- 18 Blondeau K, Dupont LJ, Mertens V, Tack J, Sifrim D. Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. *Aliment Pharmacol Ther* 2007;25(6):723-32.
- 19 Smith JA, Abdulqawi R, Houghton LA. GERD-related cough: pathophysiology and diagnostic approach. *Curr Gastroenterol Rep* 2011;13(3):247-56.
- 20 Irwin RS, Zawacki JK, Curley FJ, French CL, Hoffman PJ. Chronic cough as the sole presenting manifestation of gastroesophageal reflux. *Am Rev Respir Dis* 1989;140(5):1294-300.
- 21 Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. *Am J Respir Crit Care Med* 1994;149(1):160-7.
- 22 Benini L, Ferrari M, Sembenini C, *et al.* Cough threshold in reflux oesophagitis: influence of acid and of laryngeal and oesophageal damage. *Gut* 2000;46(6):762-7.
- 23 Javorkova N, Varechova S, Pecova R, *et al.* Acidification of the oesophagus acutely increases the cough sensitivity in patients with gastro-oesophageal reflux and chronic cough. *Neurogastroenterol Motil* 2008;20(2):119-24.
- 24 Benini L, Ferrari M, Talamini G, Vantini I. Reflux associated cough is usually not associated with reflux: role of reduced cough threshold. *Gut* 2006;55(4):583; author reply 584.
- 25 Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. *Gut* 2005;54(4):449-54.
- 26 Smith JA, Decalmer S, Kelsall A, *et al.* Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. *Gastroenterology* 2010;139(3):754-62.
- 27 Kahrilas PJ. Chronic cough and gastroesophageal reflux disease: new twists to the riddle. *Gastroenterology* 2010;139(3):716-18.
- 28 Irwin RS, French CL, Curley FJ, Zawacki JK, Bennett FM. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. *Chest* 2009;136(5 Suppl):e30.
- 29 Morice AH, Faruqi S, Wright CE, Thompson R, Bland JM. Cough hypersensitivity syndrome: a distinct clinical entity. *Lung* 2011;189(1):73-9.
- 30 Maldonado A, Diederich L, Castell DO, Gideon RM, Katz PO. Laryngopharyngeal reflux identified using a new catheter design: defining normal values and excluding artifacts. *Laryngoscope* 2003;113(2):349-55.
- 31 Paterson WG, Murat BW. Combined ambulatory esophageal manometry and dualprobe pH-metry in evaluation of patients with chronic unexplained cough. *Dig Dis Sd* 1994;39(5):1117-25.

- 32 Chang AB, Connor FL, Petsky HL, *et al.* An objective study of acid reflux and cough in children using an ambulatory pHmetry-cough logger. *Arch Dis Child* 2011; 96(5):468-72.
- 33 Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. *Gut* 2005;54(12):1810-17.
- 34 Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. *Gastroenterology* 1994;107(6):1741-5.
- 35 Hersh MJ, Sayuk GS, Gyawali CP. Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough. *J Clin Gastroenterol* 2010;44(4):254-60.
- 36 Morice AH, McGarvey L, Pavord I, British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. *Thorax* 2006;61(Suppl 1):i1-24.
- 37 Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. *Chest* 2003;123(3):679-84.
- 38 Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. *Eur Respir J* 2000;16(4):633-8.
- 39 Ours TM, Kavuru MS, Schilz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. *Am J Gastroenterol* 1999;94(11):3131-8.
- 40 Poe RH, Harder RV, Israel RH, Kallay MC. Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol. *Chest* 1989;95(4):723-8.
- 41 Shaheen NJ, Crockett SD, Bright SD, *et al.* Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2011;33(2):225-34.
- 42 Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. *Cochrane Database Syst Rev* 2011;1:CD004823.
- 43 Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. *Aliment Pharmacol Ther* 2003;17(2):243-51.
- 44 Dicipinigitais PV, Grimm DR, Lesser M. Baclofen-induced cough suppression in cervical spinal cord injury. *Arch Phys Med Rehabil* 2000;81 (7):921-3.
- 45 Lehmann A. GABAB receptors as drug targets to treat gastroesophageal reflux disease. *Pharmacol Ther* 2009;122(3):239-45.
- 46 Trulock EP, Edwards LB, Taylor DO, *et al.* Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report -2006. *J Heart Lung Transplant* 2006;25(8):880-92.

- 47 Benden C, Aurora P, Curry J, Whitmore P, Priestley L, Elliott MJ. High prevalence of gastroesophageal reflux in children after lung transplantation. *Pediatr Pulmonol* 2005;40(1):68-71.
- 48 D'Ovidio F, Mura M, Ridsdale R, *et al.* The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. *Am J Transplant* 2006;6(8):1930-8.
- 49 Mertens V, Blondeau K, Pauwels A, *et al.* Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. *Dig Dis Sci* 2009;54(5):972-9.
- 50 Draaisma WA, Rijnhart-de Jong HG, Broeders IA, Smout AJ, Furnee EJ, Gooszen HG. Five-year subjective and objective results of laparoscopic and conventional Nissen fundoplication: a randomized trial. *Ann Surg* 2006;244(1):34-41.
- 51 Lindeboom MA, Ringers J, Straathof JW, van Rijn PJ, Neijenhuis P, Masdee AA. Effect of laparoscopic partial fundoplication on reflux mechanisms. *Am J Gastroenterol* 2003;98(1):29-34.
- 52 Bredenoord AJ, Draaisma WA, Weusten BL, Gooszen HG, Smout AJ. Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. *Gut* 2008;57(2):161-6.
- 53 Broeders JA, Bredenoord AJ, Hazebroek EJ, Broeders IA, Gooszen HG, Smout AJ. Effects of anti-reflux surgery on weakly acidic reflux and belching. *Gut* 2011; 60(4):435-41.
- 54 Mainie I, Tutuian R, Agrawal A, *et al.* Fundoplication eliminates chronic cough due to non-acid reflux identified by impedance pH monitoring. *Thorax* 2005;60(6):521-3.
- 55 Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intra-luminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. *Br J Surg* 2006; 93(12):1483-7.
- 56 So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastro-esophageal reflux treated by laparoscopic fundoplication. *Surgery* 1998;124(1): 28-32.
- 57 Irwin RS, Zawacki JK, Wilson MM, French CT, Callery MP. Chronic cough due to gastroesophageal reflux disease: failure to resolve despite total/near-total elimination of esophageal acid. *Chest* 2002;121(4):1132-40.
- 58 Allen CJ, Anvari M. Preoperative symptom evaluation and esophageal acid infusion predict response to laparoscopic Nissen fundoplication in gastroesophageal reflux patients who present with cough. *Surg Endosc* 2002;16(7):1037-41.
- 59 Allen CJ, Anvari M. Does laparoscopic fundoplication provide long-term control of gastroesophageal reflux related cough? *Surg Endosc* 2004;18(4):633-7.
- 60 Galmiche JP, Zerbib F, Bruley des Varannes S. Review article: respiratory manifestations of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2008;27(6): 449-64.

## Literatura

- 1 Locke G III, Talley NJ, Fett S, Zinsmeister A, Melton L III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997;112:1448-56.
- 2 Orr WC. Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity. *Aliment Pharmacol Ther* 2010;31(1):47-56.
- 3 Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2009;7(4):372-8; quiz 367.
- 4 Shaker R, Brunton S, Elfant A, Golopol L, Ruoff G, Stanghellini V. Review article: impact of night-time reflux on lifestyle - unrecognized issues in reflux disease. *Aliment Pharmacol Ther* 2004;20(Suppl 9):3-13.
- 5 Farup C, Kleinman L, Sloan S, *et al.* The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. *Arch Intern Med* 2001;161(1):45-52.
- 6 Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. *Am J Gastroenterol* 2003;98(7):1487-93.
- 7 Schey R, Dickman R, Parthasarathy S, *et al.* Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. *Gastroenterology* 2007;133(6):1787-95.
- 8 Maneerattanaporn M, Chey WD. Sleep disorders and gastrointestinal symptoms: chicken, egg or vicious cycle? *Neurogastroenterol Motil* 2009;21(2):97-99.
- 9 Adachi K, Fujishiro H, Katsube T, *et al.* Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. *J Gastroenterol Hepatol* 2001;16(11):1191-6.
- 10 Frazzoni M, de Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. *Aliment Pharmacol Ther* 2003;18(11-12):1091-8.
- 11 Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340(11):825-31.
- 12 Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'reflux laryngitis'. *Gastroenterology* 1991;100(2):305-10.
- 13 Pellegrini CA, DeMeester TR, Johnson LF, Skinner DB. Gastroesophageal reflux and pulmonary aspiration: incidence, functional abnormality, and results of surgical therapy. *Surgery* 1979;86(1):110-19.

- 14 Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. *Am J Respir Crit Care Med* 2000; 162(1):34-9.
- 15 Dean BB, Aguilar D, Johnson LF, *et al.* Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: frequency, severity and impact on health-related quality of life. *Aliment Pharmacol Ther* 2008;27(4):327-37.
- 16 Cuttitta G, Cibella F, Visconti A, Scichilone N, Bellia V, Bonsignore G. Spontaneous gastroesophageal reflux and airway patency during the night in adult asthmatics. *Am J Respir Crit Care Med* 2000;161(1):177-81.
- 17 Fass R. The relationship between gastroesophageal reflux disease and sleep. *Curr Gastroenterol Rep* 2009;11(3):202-8.
- 18 Wilson JF. Is sleep the new vital sign? *Ann Intern Med* 2005;142(10):877-80.
- 19 Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup Survey conducted on behalf of the American Gastroenterological Association. *Am J Gastroenterol* 2003;98(7):1487-93.
- 20 Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. *Am J Gastroenterol* 1996;1996(91):9.
- 21 Farup C, Kleinman L, Sloan S, *et al.* The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. *Arch Intern Med* 2001;161(1):1448-56.
- 22 Fass R, Quan SF, O'Connor GT, Ervin A, Iber C. Predictors of heartburn during sleep in a large prospective cohort study. *Chest* 2005;127(5):1658-66.
- 23 Fornari F, Madalosso CAS, Callegari-Jacques SM, Gurski RR. Heartburn during sleep: a clinical marker of gastro-oesophageal reflux disease in morbidly obese patients. *Neurogastroenterol Motil* 2009;21(2):136-42.
- 24 Fass R. Poorly recognized reflux-induced symptoms. *Eur J Gastroenterol Hepatol* 2001;13(Suppl 3):S32-S34.
- 25 Dean BB, Aguilar D, Johnson LF, *et al.* Night-time and daytime atypical manifestations of gastro-oesophageal reflux disease: frequency, severity and impact on health-related quality of life. *Aliment Pharmacol Ther* 2008;27:327-37.
- 26 Gislason T, Janson C, Vermeire P *et al.* Respiratory symptoms and nocturnal gastro-esophageal reflux: a population-based study of young adults in three European countries. *Chest* 2002;121(1):158-63.
- 27 Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. *Clin Gastroenterol Hepatol* 2009;7(9):953-9.
- 28 Orr WC, Robinson MG, Johnson LF. Acid clearance during sleep in the pathogenesis of reflux esophagitis. *Dig Dis Sci* 1981;26(5):423-7.
- 29 Orr WC, Robinson MG, Johnson LF. The effect of esophageal acid volume on arousals from sleep and acid clearance. *Chest* 1991;99(2):351-4.
- 30 Orr WC, Johnson LF. Responses to different levels of esophageal acidification during waking and sleeping. *Dig Dis Sci* 1998;43(2):241-5.

- 31 Orr WC, Elsenbruch S, Harnish MJ, Johnson LF. Proximal migration of esophageal acid perfusions during waking and sleep. *Am J Gastroenterol* 2000;95(1):37-42.
- 32 Schneyer LH, Pigman W, Hanahan L, Gilmore RW. Rate of flow of human parotid, sublingual, and submaxillary secretions during sleep. *J Dent Res* 1956;35(1):109-14.
- 33 Lear CS, Flanagan JB Jr, Moorrees CF. The frequency of deglutition in man. *Arch Oral Biol* 1965;10:83-100.
- 34 Eastwood PR, Katagiri S, Shepherd KL, Hillman DR. Modulation of upper and lower esophageal sphincter tone during sleep. *Sleep Med* 2007;8(2):135-43.
- 35 Avots-Avotins AE, Ashworth WD, Stafford BD, Moore JG. Day and night esophageal motor function. *Am J Gastroenterol* 1990;85(6):683-5.
- 36 Dent J, Dodds WJ, Friedman RH, *et al.* Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980;65(2):256-67.
- 37 Freidin N, Fisher MJ, Taylor W, *et al.* Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. *Gut* 1991;32(11):1275-9.
- 38 Shaker R, Hogan WJ. Reflex-mediated enhancement of airway protective mechanisms. *Am J Med* 2000;108(Suppl 4a):8S-14S.
- 39 Lang IM, Medda BK, Shaker R. Mechanisms of reflexes induced by esophageal distension. *Am J Physiol* 2001;281(5):G1246-63.
- 40 Enzmann DR, Harell GS, Zboralske FF. Upper esophageal responses to intraluminal distention in man. *Gastroenterology* 1977;72(6):1292-8.
- 41 Schoeman MN, Holloway RH. Stimulation and characteristics of secondary oesophageal peristalsis in normal subjects. *Gut* 1994;35(2):152-8.
- 42 Castiglione F, Emde C, Armstrong D, *et al.* Nocturnal oesophageal motor activity is dependent on sleep stage. *Gut* 1993;34(12):1653-9.
- 43 Dent J, Dodds WJ, Friedman RH, *et al.* Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980;65(2):256-67.
- 44 Bajaj JS, Bajaj S, Dua KS, *et al.* Influence of sleep stages on esophago-upper esophageal sphincter contractile reflex and secondary esophageal peristalsis. *Gastroenterology* 2006;130(1):17-25.
- 45 Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric emptying of meals in humans. *Gastroenterology* 1987;93(3):515-18.
- 46 Elsenbruch S, Orr WC, Harnish MJ, Chen JD. Disruption of normal gastric myoelectric functioning by sleep. *Sleep* 1999;22(4):453-8.
- 47 Pasricha PJ. Effect of sleep on gastroesophageal physiology and airway protective mechanisms. *Am J Med* 2003;115(Suppl 3A):114S-118S.
- 48 Orr WC, Lackey C, Robinson MG, Johnson LF, Welsh JD. Esophageal acid clearance during sleep in patients with Barrett's esophagus. *Dig Dis Sci* 1988;33(6):654-9.
- 49 Hila A, Castell DO. Nighttime reflux is primarily an early event. *J Clin Gastroenterol* 2005;39(7):579-83.

- 50 Dickman R, Shapiro M, Malagon IB, Powers J, Fass R. Assessment of 24-h oesophageal pH monitoring should be divided to awake and asleep rather than upright and supine time periods. *Neurogastroenterol Motil* 2007;19(9):709-15.
- 51 Mizyed I, Allen LM, Navarro-Rodriguez T, *et al.* Actigraphy is a simple and accurate technique to determine esophageal acid exposure during sleep in patients undergoing pH testing. *Gastroenterology* 2008;134(4 Suppl 1):T2004, P-284.
- 52 Dickman R, Parthasarathy S, Malagon IB, *et al.* Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro- oesophageal reflux disease groups. *Aliment Pharmacol Ther* 2007;26(1):41-8.
- 53 Fujiwara Y, Machida A, Watanabe Y, *et al.* Association between dinner-to-bed time and gastro-esophageal reflux disease. *Am J Gastroenterol* 2005;100:2633-6.
- 54 Piesman M, Hwang I, Maydonovitch C, Wong RKH. Nocturnal reflux episodes following administration of a standardized meal. Does timing matter? *Am J Gastroenterol* 2007;102:2128-34.
- 55 Happe MR, Maydonovitch CL, Belle L, Gorske AC, Wong RKH. Not eating close to bedtime - is this good advice? The relationship between dinner and supine reflux. *Gastroenterology* 2004;126(4 (Suppl 2)):#T1732, A-501.
- 56 Yi CH, Hu CT, Chen CL. Sleep dysfunction in patients with GERD: erosive versus nonerosive reflux disease. *Am J Med Sci* 2007;334(3):168-70.
- 57 Morgenthaler T, Alessi C, Friedman L, *et al.* Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. *Sleep* 2007;30(4):519-29.
- 58 Hershcovici T, Gasiorowska A, Fass R. Advancements in the analysis of esophageal pH monitoring in GERD. *Nat Rev Gastroenterol Hepatol* 2011;8(2):101-7.
- 59 Poh CH, Gasiorowska A, Allen L, *et al.* Reassessment of the principal characteristics of gastroesophageal reflux during the recumbent period using integrated actigraphy- acquired information. *Am J Gastroenterol* 2010;105(5):1024-31.
- 60 Poh CH, Allen L, Malagon I, *et al.* Riser's reflux - an eye-opening experience. *Neurogastroenterol Motil* 2010;22(4):387-94.
- 61 Poh CH, Allen L, Gasiorowska A, *et al.* Conscious awakenings are commonly associated with acid reflux events in patients with gastroesophageal reflux disease. *Clin Gastroenterol Hepatol* 2010;8(10):851-7.
- 62 Allen L, Poh CH, Gasiorowska A, *et al.* Increased oesophageal acid exposure at the beginning of the recumbent period is primarily a recumbent-awake phenomenon. *Aliment Pharmacol Ther* 2010;32(6):787-94.
- 63 Poh CH, Allen LM, Gasiorowska A, *et al.* Acid reflux and arousals: which is the chicken, and which is the egg? *Gastroenterology* 2009;136(5:Suppl 1):#S1891, A-286.
- 64 Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. *Aliment Pharmacol Ther* 2005;21(2):103-8.
- 65 Budhiraja R, Quan SF, Punjabi NM, Drake CL, Dickman R, Fass R. Power spectral analysis of the sleep electroencephalogram in heartburn patients with

- or without gastroesophageal reflux disease: a feasibility study. *J Clin Gastroenterol* 2010; 44(2):91-6.
- 66 Hershcovici T, Gasiorowska A, Poh CH, *et al.* The differential effect of sleep deprivation versus good sleep on esophageal acid exposure in normal subjects. *Gastroenterology* 2010;138(Suppl 5):S-603.
- 67 Farmer W, Yaffe J, Santiago T. Managing sleep disorders in military personnel. *Federal Pract* 2002;19:21-39.
- 68 Kerr P, Shoenuit JP, Millar T, Buckle P, Kryger MH. Nasal CPAP reduces gastroesophageal reflux in obstructive sleep apnea syndrome. *Chest* 1992;101(6):1539-44.
- 69 Gleeson K, Zwillch CW, White DP. The influence of increasing ventilatory effort on arousal from sleep. *Am Rev Respir Dis* 1990;142:295-300.
- 70 Kuribayashi S, Massey BT, Hafeezullah M, *et al.* Upper esophageal sphincter and gas-troesophageal junction pressure changes act to prevent gastroesophageal and esoph- agopharyngeal reflux during apneic episodes in patients with obstructive sleep apnea. *Chest* 2010;137(4):769-76.
- 71 Tawk M, Goodrich S, Kinasewitz G, Orr W. The effect of 1 week of continuous positive airway pressure treatment in obstructive sleep apnea patients with concomitant gastroesophageal reflux. *Chest* 2006;130(4):1003-8.
- 72 Penzel T, Becker HF, Brandenburg U, *et al.* Arousal in patients with gastro-oesophageal reflux and sleep apnoea. *Eur Respir J* 1999;14:1266-70.
- 73 Graf KI, Karaus M, Heinemann S, Korber S, Dorow P, Hampel KE. Gastroesophageal reflux in patients with sleep apnea syndrome. *Z Gastroenterol* 1995;33(12):689-93.
- 74 Morse CA, Quan SF, Mays MZ, Green C, Stephen G, Fass R. Is there a relationship between obstructive sleep apnea and gastroesophageal reflux disease? *Clin Gastroenterol Hepatol* 2004;2(9):761-8.
- 75 Kim H, Vorona R, Winn M, Doviak M, Johnson D, Ware J. Symptoms of gastro-oesophageal reflux disease and the severity of obstructive sleep apnoea syndrome are not related in sleep disorders center patients. *Aliment Pharmacol Ther* 2005; 21(9):1127-33.
- 76 Orr WC. Heartburn: another danger in the night? *Chest* 2005;127(5):1486-8.
- 77 Dekel R, Green C, Malagon I, *et al.* Short, spontaneous, anamnestic arousals are the most common sleep abnormality associated with nocturnal esophageal acid exposure. *Gastroenterology* 2003;124(4 Supplement 1):A-412 (M 2087).
- 78 Orr WC, Goodrich S, Fernstrom P, Hasselgren G. Occurrence of nighttime gastro-esophageal reflux in disturbed and normal sleepers. *Clin Gastroenterol Hepatol* 2008;6(10):1099-104.
- 79 Wilder-Smith C, Rohss K, Bokelund Singh S, Sagar M, Nagy P. The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers. *Aliment Pharmacol Ther* 2010;32(10):1249-56.



- 80 Chand N, Johnson DA, Tabangin M, Ware JC. Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study. *Aliment Pharmacol Ther* 2004;20(9):969-74.
- 81 Johnson DA, Orr WC, Crawley JA, *et al.* Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. *Am J Gastroenterol* 2005;100(9):1914-22.
- 82 Dimarino A Jr, Banwait K, Eschinger E, *et al.* The effect of gastro-oesophageal reflux and omeprazole on key sleep parameters. *Aliment Pharmacol Ther* 2005;22(4):325-9.
- 83 DeVault K, Holtmann J, Malagelada J, Schmitt H, Chassany O. Pantoprazole 40 mg (PANTO) is superior to esomeprazole 40 mg (ESO) in resolving sleep disturbances in GERD patients (abstract). *Am J Gastroenterol* 2006;101(9):S399-S400.
- 84 Fass R, Johnson DA, Orr WC, *et al.* The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. *Am J Gastroenterol* 2011;106(3):421-31.
- 85 Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2005;21(12): 1467-74.
- 86 Katz PO, Koch FK, Ballard ED, *et al.* Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. *Aliment Pharmacol Ther* 2007;25(2): 197-205.
- 87 Warrington S, Baisley K, Kee D, *et al.* Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. *Aliment Pharmacol Ther* 2007;25(4):511-17.
- 88 Rackoff A, Agrawal A, Hila I, Mamie I, Tutuiian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. *Dis Esophagus* 2005;18:370-3.
- 89 Janiak P, Thumshirn M, Menne D, *et al.* Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis - a randomized controlled, cross-over trial. *Aliment Pharmacol Ther* 2007;26(9):1259-65.
- 90 Orr WC, Craddock A, Goodrich S. Acidic and non-acidic reflux during sleep under conditions of powerful acid suppression. *Chest* 2007;131(2):460-5.
- 91 Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. *Am J Gastroenterol* 1998; 93(5):763-7.
- 92 Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. *Aliment Pharmacol Ther* 2002;16(7):1309-16.

- 93 Cohen JA, Harris PA, Byrne DW, Holzman MD, Sharp KW, Richards WO. Surgical trial investigating nocturnal gastroesophageal reflux and sleep (STINGERS). *Surg Endosc* 2003;17:394-400.
- 94 Gagliardi GS, Shah AP, Goldstein M, *et al.* Effect of zolpidem on the sleep arousal response to nocturnal esophageal acid exposure. *Clin Gastroenterol Hepatol* 2009; 7(9):948-52.

## Literatura

- 1 Poudoux P, Ergun GA, Lin S, Kahrilas PJ. Esophageal bolus transit imaged by ultrafast computerized tomography. *Gastroenterology* 1996;110(5):1422-8.
- 2 Johnson HD, Laws JW. The cardia in swallowing, eructation, and vomiting. *Lancet* 1966;2(7476):1268-73.
- 3 Zerbib F, des Varannes SB, Ropert A, Lamouliatte H, Quinton A, Galmiche JP. Proximal gastric tone in gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol* 1999;11(5):511-15.
- 4 Penagini R, Carmagnola S, Cantu P, Allocca M, Bianchi PA. Mechanoreceptors of the proximal stomach: role in triggering transient lower esophageal sphincter relaxation. *Gastroenterology* 2004;126(1):49-56.
- 5 McNally EF, Kelly E, Ingelfinger F. Mechanism of belching: effects of gastric distention with air. *Gastroenterology* 1964;46:254-9.
- 6 Mittal RK, Fisher MJ. Electrical and mechanical inhibition of the crural diaphragm during transient relaxation of the lower esophageal sphincter. *Gastroenterology* 1990;99(5):1265-8.
- 7 Kahrilas PJ, Dodds WJ, Dent J, Wyman JB, Hogan WJ, Arndorfer RC. Upper esophageal sphincter function during belching. *Gastroenterology* 1986;91(1):133-40.
- 8 Enzmann DR, Harell GS, Zboralske FF. Upper esophageal responses to intraluminal distention in man. *Gastroenterology* 1977;72(6):1292-8.
- 9 Shaker R, Ren J, Kern M, Dodds WJ, Hogan WJ, Li Q. Mechanisms of airway protection and upper esophageal sphincter opening during belching. *Am J Physiol* 1992;262(4 Pt 1):G621-G628.
- 10 Wyman JB, Dent J, Heddle R, Dodds WJ, Toouli J, Downton J. Control of belching by the lower oesophageal sphincter. *Gut* 1990;31(6):639-46.
- 11 Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. *Lancet* 1990;335(8683):205-8.
- 12 Straathof JW, Ringers J, Lamers CB, Masclee AA. Provocation of transient lower esophageal sphincter relaxations by gastric distension with air. *Am J Gastroenterol* 2001;96(8):2317-23.
- 13 Sifrim D, Silny J, Holloway RH, Janssens JJ. Patterns of gas and liquid reflux during transient lower oesophageal sphincter relaxation: a study using intraluminal electrical impedance. *Gut* 1999;44(1):47-54.
- 14 Bredenoord AJ, Weusten BL, Timmer R, Akkermans LM, Smout AJ. Relationships between air swallowing, intragastric air, belching and gastro-oesophageal reflux. *Neurogastroenterol Motil* 2005;17(3):341-7.
- 15 Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Air swallowing, belching, and reflux in patients with gastroesophageal reflux disease. *Am J Gastroenterol* 2006;101(8):1721-6.

- 16 Hemmink GJ, Weusten BL, Bredenoord AJ, Timmer R, Smout AJ. Increased swallowing frequency in GORD is likely to be caused by perception of reflux episodes. *Neurogastroenterol Motil* 2009;21(2):143-8.
- 17 Kamolz T, Bammer T, Granderath FA, Pointner R. Comorbidity of aerophagia in GERD patients: outcome of laparoscopic antireflux surgery. *Scand J Gastroenterol* 2002;37(2):138-43.
- 18 Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. *Gut* 2005;55(3):313-18.
- 19 Barish CF, Castell DO, Richter JE. Graded esophageal balloon distention. A new pro-vocative test for noncardiac chest pain. *Dig Dis Sci* 1986;31(12):1292-8.
- 20 Kahrilas PJ, Dodds WJ, Hogan WJ. Dysfunction of the belch reflex. A cause of inca-pacitating chest pain. *Gastroenterology* 1987;93(4):818-22.
- 21 Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. *Gut* 2002;50(1):19-24.
- 22 Lin M, Triadafilopoulos G. Belching: dyspepsia or gastroesophageal reflux disease? *Am J Gastroenterol* 2003;98(10):2139-45.
- 23 Camilleri M, Dubois D, Coulie B, *et al.* Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. *Clin Gastroenterol Hepatol* 2005;3(6):543-52.
- 24 Conchillo JM, Selimah M, Bredenoord AJ, Samsom M, Smout AJ. Air swallowing, belching, acid and non-acid reflux in patients with functional dyspepsia. *Aliment Pharmacol Ther* 2007;25(8):965-71.
- 25 Bredenoord AJ, Smout AJ. Impaired health-related quality of life in patients with excessive supragastric belching. *Eur J Gastroenterol Hepatol* 2010;22(12):1420-3.
- 26 Chitkara DK, Bredenoord AJ, Tucker MJ, Talley NJ. Aerophagia in adults: a comparison of presenting symptoms with functional dyspepsia. *Aliment Pharmacol Ther* 2005;22(9):855-8.
- 27 Bredenoord AJ, Weusten BL, Sifrim D, Timmer R, Smout AJ. Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. *Gut* 2004;53(11):1561-5.
- 28 [No authors listed] Physiology of belch. *Lancet* 1991;337(8732):23-4.
- 29 Tack J, Talley NJ, Camilleri M, *et al.* Functional gastroduodenal disorders. *Gastroenterology* 2006;130(5):1466-79.
- 30 Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Psychological factors affect the frequency of belching in patients with aerophagia. *Am J Gastroenterol* 2006; 101(12):2777-81.
- 31 Roth JLA. Aerophagia. In: Linder AE (ed) *Emotional factors in gastrointestinal illness*. Amsterdam: Excerpta Medica, 1973: pp.16-36.
- 32 Cigrang JA, Hunter CM, Peterson AL. Behavioral treatment of chronic belching due to aerophagia in a normal adult. *Behav Modif* 2006;30(3):341-51.
- 33 Chitkara DK, Bredenoord AJ, Talley NJ, Whitehead WE. Aerophagia and rumination: recognition and therapy. *Curr Treat Options Gastroenterol* 2006;9(4): 305-13.

- 34 Damste PH. Methods of restoring the voice after laryngectomy. *Laryngoscope* 1975; 85(4):649-55.
- 35 Hemmink GJ, Ten Cate L, Bredenoord AJ, Timmer R, Weusten BL, Smout AJ. Speech therapy in patients with excessive supragastric belching - a pilot study. *Neurogastroenterol Motil* 2010;22(1): 24-8.
- 36 Spiegel SB. Uses of hypnosis in the treatment of uncontrollable belching: a case report. *Am J Clin Hypn* 1996;38(4):263-70.
- 37 Bassotti G, Whitehead WE. Biofeedback as a treatment approach to gastrointestinal tract disorders. *Am J Gastroenterol* 1994;89(2):158-64.
- 38 Zella SJ, Geenens DL, Horst JN. Repetitive eructation as a manifestation of obsessive-compulsive disorder. *Psychosomatics* 1998;39(3):299-301.
- 39 Smith D, King NA, Waldron B, *et al.* Study of belching ability in antireflux surgery patients and normal volunteers. *Br J Surg* 1991;78(1):32-5.
- 40 Scheffer RC, Tatum RP, Shi G, Akkermans LM, Joehl RJ, Kahrilas PJ. Reduced tLESR elicitation in response to gastric distension in fundoplication patients. *Am J Physiol Gastrointest Liver Physiol* 2003;284(5):G815-G820.
- 41 Bredenoord AJ, Draaisma WA, Weusten BL, Gooszen HG, Smout AJ. Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. *Gut* 2008;57(2):161-6.
- 42 Broeders JA, Bredenoord AJ, Hazebroek EJ, Broeders IA, Gooszen HG, Smout AJ. Effects of antireflux surgery on weakly acidic reflux and belching. *Gut* 2011;60(4): 435-41.
- 43 Gauderer MW, Halpin TC Jr, Izant RJ Jr. Pathologic childhood aerophagia: a recognizable clinical entity. *J Pediatr Surg* 1981;16(3):301-5.
- 44 Hackl H. Pathologische arophagie als todesursache. *Med Klin* 1973;68(20):667-9.
- 45 Hemmink GJ, Weusten BL, Bredenoord AJ, Timmer R, Smout AJ. Aerophagia: excessive air swallowing shown by esophageal impedance monitoring. *Clin Gastroenterol Hepatol* 2009;7(10):1127-9.
- 46 Fonagy P, Calloway SP. The effect of emotional arousal on spontaneous swallowing rates. *J Psychosom Res* 1986;30(2):183-8.
- 47 Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in irritable bowel syndrome. *Gastroenterology* 2002;123(3):700-6.
- 48 Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. *Gastroenterology* 2002;122(7):1748-55.
- 49 Houghton LA, Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. *Neurogastroenterol Motil* 2005;17(4):500-11.

## Literatura

- 1 Lindgren MD, Janzon L. Prevalence of swallowing complaints and clinical findings among 50-70 year old men and women in an urban population. *Dysphagia* 1991;6:187-92.
- 2 Katz KO, Anand G. Dysphagia and esophageal obstruction. In: Bope ET, Kellerman R, Rakel RE (eds) *Conn's current therapy*. Philadelphia: Elsevier, 2011: pp.523-6.
- 3 Wilcox CM, Alexander LN, Clark WS. Localization of an obstructing esophageal lesion. Is the patient accurate? *Dig Dis Sci* 1995;40:2192-6.
- 4 Spechler SG. American Gastroenterological Association technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. *Gastroenterology* 1999; 177:233-54.
- 5 Ruigomez A, Garcia Rodriguez LA, Wallander MA, Johansson S, Eklund S. Esophageal stricture: incidence, treatment patterns, and recurrence rate. *Am J Gastroenterol* 2006;101:2685-92.
- 6 Siersema, PD. Strictures, rings, and webs. In: Talley NJ, DeVault KR, Fleischer DE (eds) *Practical gastroenterology and hepatology: esophagus and stomach*. Oxford: Wiley-Blackwell, 2010: pp.276-8.
- 7 Schatski R. The lower esophageal ring. Long term follow-up of symptomatic and asymptomatic rings. *Am J Roentgenol Radium Ther Nucl Med* 1963;90:805-10.
- 8 Piotet E, Escher A, Monnier P. Esophageal and pharyngeal strictures: report of 1,862 endoscopic dilations using the Savary-Gilliard technique. *Eur Arch Otorhinolaryngol* 2008;265:357-64.
- 9 Lew RJ, Kochman ML. A review of endoscopic methods of esophageal dilation. *J Clin Gastroenterol* 2002;35:117-26.
- 10 Schatzki R, Gary J. Dysphagia due to a diaphragm-like localized narrowing in the lower esophagus ("lower esophageal ring"). *Am J Roentgenol* 1953;70:911-22.
- 11 Sgouros SN, Vlachogiannakos J, Karamanolis G, *et al.* Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings: a prospective, randomized, placebo-controlled study. *Am J Gastroenterol* 2005;100(9):1929-34.
- 12 Nurko S, Teitelbaum JE, Husain K, *et al.* Association of Schatzki ring with eosinophilic esophagitis in children. *J Pediatr Gastroenterol Nutr* 2004;38:436-41.
- 13 Novacek G. Plummer-Vinson syndrome. *Orphanet J Rare Dis* 2006;1:36.
- 14 Thun MJ, Peto R, Lopez AD, *et al.* Alcohol consumption and mortality among middle-aged and elderly U.S. adults. *N Engl J Med* 1997;337:1705-14.
- 15 Zhai R, Chen F, Liu G, *et al.* Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. *J Clin Oncol* 2010;28:2445-51.

- 16 Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. *Lancet* 2002;360:1587-9.
- 17 Mendes de Almeida JC, Chaves P, Pereira AD, Altorki NK. Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. *Ann Surg* 1997;226:725-33;discussion 733-5.
- 18 Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. *Am J Gastroenterol* 1999;94:86-91.
- 19 Smith MS, Lightdale CJ. Esophageal cancer. In: Talley NJ, DeVault KR, Fleischer DE (eds) *Practical gastroenterology and hepatology: esophagus and stomach*. Oxford: Wiley- Blackwell, 2010: pp.320-3.
- 20 Cooper JS, Guo MD, Herskovic A, *et al.* Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). *JAMA* 1999;281:1623-7.
- 21 Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. *Gastroenterology* 1991;101:1149-58.
- 22 Little AG, DeMeester TR, Kirchner PT, O'Sullivan GC, Skinner DB. Pathogenesis of esophagitis in patients with gastroesophageal reflux. *Surgery* 1980;88:101-7.
- 23 Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. *Clin Gastroenterol Hepatol* 2004;2:665-8.
- 24 Prasad GA, Talley NJ, Romero Y, *et al.* Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. *Am J Gastroenterol* 2007 102:2627-32.
- 25 Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. *Am J Gastroenterol* 2007;102:1301-6.
- 26 Tutuian R, Castell DO. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance- manometry. *Clin Gastroenterol Hepatol* 2004;2(3):230-6.
- 27 Ho SC, Chang CS, Wu CY, Chen GH. Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. *Dig Dis Sci* 2002;47:652-6.
- 28 Richter JE, Hackshaw BT, Wu WC, Castell DO. Edrophonium: a useful provocative test for esophageal chest pain. *Ann Intern Med* 1985;103:14-21.
- 29 Humphries TJ, Castell DO. Effect of oral bethanechol on parameters of esophageal peristalsis. *Dig Dis Sci* 1981;26:129-32.
- 30 Blonski W, Vela MF, Freeman J, Sharma N, Castell DO. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. *J Clin Gastroenterol* 2009;43:253-60.
- 31 Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. *Br J Rheumatol* 1989;28:281-6.

- 32 D'Angelo WA, Fries JF Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. *Am J Med* 1969;46:428-40.
- 33 Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. *J Clin Invest* 1972;51:2663-8.



## Literatura

- 1 Liacouras CA, Furuta GT, Hirano I, *et al.* Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol* 2011;128(1):3-20.
- 2 Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. *Gastrointest Endosc* 2006;63(1):3-12.
- 3 Shah A, Kagalwalla AF, Gonsalves N, Melin-Aldana H, Li BU, Hirano I. Histopathologic variability in children with eosinophilic esophagitis. *Am J Gastroenterol* 2009;104(3):716-21.
- 4 Teitelbaum JE, Fox VL, Twarog FJ, *et al.* Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. *Gastroenterology* 2002;122(5):1216-25.
- 5 Rodrigo S, Abboud G, Oh D, *et al.* High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. *Am J Gastroenterol* 2008;103(2):435-42.
- 6 Winter HS, Madara JL, Stafford RJ, Grand RJ, Quinlan JE, Goldman H. Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. *Gastroenterology* 1982;83(4):818-23.
- 7 Molina-Infante J, Ferrando-Lamana L, Mateos-Rodriguez JM, Perez-Gallardo B, Prieto-Bermejo AB. Overlap of reflux and eosinophilic esophagitis in two patients requiring different therapies: a review of the literature. *World J Gastroenterol* 2008;14(9):1463-6.
- 8 Molina-Infante J, Ferrando-Lamana L, Ripoll C, *et al.* Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. *Clin Gastroenterol Hepatol*; 9(2):110-17.
- 9 Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus - peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. *Am J Gastroenterol* 2006;101(7):1666-70.
- 10 Furuta GT, Liacouras CA, Collins MH, *et al.* Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology* 2007;133(4):1342-63.
- 11 Desai TK, Stecevic V, Chang CH, Goldstein NS, Badizadegan K, Furuta GT. Association of eosinophilic inflammation with esophageal food impaction in adults. *Gastrointest Endosc* 2005;61(7):795-801.
- 12 Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. *N Engl J Med* 2004;351(9):940-1.
- 13 Liacouras CA, Spergel JM, Ruchelli E, *et al.* Eosinophilic esophagitis: a 10-year experience in 381 children. *Clin Gastroenterol Hepatol* 2005;3(12):1198-206.

- 14 Konikoff MR, Blanchard C, Kirby C, *et al.* Potential of blood eosinophils, eosinophil- derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2006;4(11):1328-36.
- 15 Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic Assessment of the Esophageal Features of Eosinophilic Esophagitis: Validation of a Novel Classification and Grading System. *Gut* 2012 In press PMID 22619364.
- 16 Fox VL, Nurko S, Teitelbaum JE, Badizadegan K, Furuta GT. High-resolution EUS in children with eosinophilic “allergic” esophagitis. *Gastrointest Endosc* 2003; 57(1):30-6.
- 17 Stevoff C, Rao S, Parsons W, Kahrilas PJ, Hirano I. EUS and histopathologic correlates in eosinophilic esophagitis. *Gastrointest Endosc* 2001;54(3):373-7.
- 18 Kwiatek MA, Hirano I, Kahrilas PJ, Rothe J, Luger D, Pandolfino JE. Mechanical properties of the esophagus in eosinophilic esophagitis. *Gastroenterology* 2011;140(1):82-90.
- 19 Roman S, Hirano I, Kwiatek MA, *et al.* Manometric features of eosinophilic esophagitis in esophageal pressure topography. *Neurogastroenterol Motil* 2011;23(3):208.
- 20 Nurko S, Rosen R, Furuta GT. Esophageal dysmotility in children with eosinophilic esophagitis: a study using prolonged esophageal manometry. *Am J Gastroenterol* 2009;104(12):3050-7.
- 21 Korsapati H, Babaei A, Bhargava V, Dohll R, Quin A, Mittal RK. Dysfunction of the longitudinal muscles of the oesophagus in eosinophilic oesophagitis. *Gut* 2009;58(8):1056-62.
- 22 Rothenberg ME. Biology and treatment of eosinophilic esophagitis. *Gastroenterology* 2009;137(4):1238-49.
- 23 Croese J, Fairley SK, Masson JW, *et al.* Clinical and endoscopic features of eosinophilic esophagitis in adults. *Gastrointest Endosc* 2003;58(4):516-22.
- 24 Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. *Dig Dis Sci* 1993;38(1):109-16.
- 25 Zimmerman SL, Levine MS, Rubesin SE, *et al.* Idiopathic eosinophilic esophagitis in adults: the ringed esophagus. *Radiology* 2005;236(1):159-65.
- 26 Parfitt JR, Gregor JC, Suskin NG, Jawa HA, Driman DK. Eosinophilic esophagitis in adults: distinguishing features from gastroesophageal reflux disease: a study of 41 patients. *Mod Pathol* 2006;19(1):90-6.
- 27 Brown LF, Goldman H, Antonioli DA. Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis. *Am J Surg Pathol* 1984;8(12):899-905.
- 28 Straumann A, Spichtin HP, Bernoulli R, Loosli J, Vogtlin J. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. *Schweiz Med Wochenschr* 1994;124(33):1419-29.

- 29 Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid- based formula. *Gastroenterology* 1995;109(5):1503-12.
- 30 Attwood SE, Fiocca R, Mastracci L, *et al.* High density eosinophilic infiltration in gastro-esophageal reflux disease is rare and probably not related to primary eosinophilic esophagitis: a cohort study from the Lotus Trial. Paper presented at Digestive Disease Week 2011; Chicago, IL.
- 31 Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. *J Pediatr* 2009;154(1):96-100.
- 32 Sayej WN, Patel R, Baker RD, Tron E, Baker SS. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2009;49(4):393-9.
- 33 Toto E, Garrean C, Hayman A, *et al.* Differentiation of GERD from EoE (eosinophilic esophagitis): predictive factors and response to PPI trial. Paper presented at Digestive Disease Week 2011; Chicago, IL.
- 34 Lee S, de Boer WB, Naran A, *et al.* More than just counting eosinophils: proximal oesophageal involvement and subepithelial sclerosis are major diagnostic criteria for eosinophilic oesophagitis. *J Clin Pathol* 2010;63(7):644-7.
- 35 Ravi K, Katzka DA, Smyrk TC, *et al.* Prevalence of esophageal eosinophils in patients with Barrett's esophagus. *Am J Gastroenterol* 2011;106(5):851-7.
- 36 Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. *Am J Gastroenterol* 2007;102(6):1301-6.
- 37 Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC. Dilated intercellular spaces and shunt permeability in nonerosive add-damaged esophageal epithelium. *Am J Gastroenterol* 2004;99(1):13-22.
- 38 Barthel SR, Annis DS, Mosher DF, Johansson MW. Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. *J Biol Chem* 2006;281(43):32175-87.
- 39 Blanchard C, Wang N, Stringer KF, *et al.* Eotaxin-3 and a uniquely conserved geneexpression profile in eosinophilic esophagitis. *J Clin Invest* 2006;116(2):536-47.
- 40 Blanchard C, Stucke EM, Burwinkel K, *et al.* Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. *J Immunol* 2010;184(7):4033-41.
- 41 Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again. *Clin Gastroenterol Hepatol* 2011;9(2):99-101.
- 42 Dellon ES, Farrell TM, Bozymski EM, Shaheen NJ. Diagnosis of eosinophilic esophagitis after fundoplication for 'refractory reflux': implications for pre-operative evaluation. *Dis Esophagus* 2010;23(3):191-5.

- 43 Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. *Dig Dis Sci* 2009;54(11):2312-17.
- 44 Garrean C, Hirano I. Eosinophilic esophagitis: pathophysiology and optimal management. *Curr Gastroenterol Rep* 2009;11(3):175-81.

## Literatura

- 1 Axon A, Forman D. *Helicobacter* gastroduodenitis: a serious infectious disease. *BMJ* 1997;314:1430-1.
- 2 Schutze K, Hentschel E, Dragosics B, Hirschl AM. *Helicobacter pylori* reinfection with identical organisms: transmission by the patients' spouses. *Gut* 1995;36:831-3.
- 3 Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing *Helicobacter pylori* infection in patients with duodenal ulcer may provoke reflux esophagitis. *Gastroenterology* 1997;112:1442-7.
- 4 Winkelstein A, Wolf BS, Som ML, Marshak RH. Peptic esophagitis with duodenal or gastric ulcer. *JAMA* 1954;154:885-9.
- 5 Winkelstein A. Peptic esophagitis with duodenal ulcer. *Am J Surg* 1957;93:234-7.
- 6 Cruze K, Byron FX, Hill JT. The association of peptic ulcers and asymptomatic hiatal hernia. *Surgery* 1959;46:664-8.
- 7 Moraes-Filho JP, Zaterka S, Pinotti HW, Bettarello A. Esophagitis and duodenal ulcer. *Digestion* 1974;11:338-46.
- 8 Moraes-Filho JP. Lack of specificity of the acid perfusion test in duodenal ulcer patients. *Am J Dig Dis* 1974;19:785-90.
- 9 Flook D, Stoddard CJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. *Br J Surg* 1985;72:804-7.
- 10 Behar J, Biancani P, Sheahan DG. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. *Gastroenterology* 1976;71:9-15.
- 11 Goldman MS Jr, Rasch JR, Wiltsie DS, Finkel M. The incidence of esophagitis in peptic ulcer disease. *Am J Dig Dis* 1967;12:994-9.
- 12 Earlam RJ, Amerigo J, Kakavoulis T, Pollock DJ. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. *Gut* 1985;26:95-100.
- 13 Boyd EJ. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. *Am J Gastroenterol* 1996;91:1539-43.
- 14 Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. *J Gastroenterol* 2009;44:518-34.
- 15 Dent J. Review article: from 1906 to 2006 - a century of major evolution of understanding of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2006; 24:1269-81.
- 16 Graham DY. The changing epidemiology of GERD: geography and *Helicobacter pylori*. *Am J Gastroenterol* 2003;98:1462-70.
- 17 Liu Y, Akiyama J, Graham DY. Current understandings of *Helicobacter pylori*, peptic ulcer and gastroesophageal reflux disease. *Minerva Gastroenterol Dietol* 2006 ;52:235-48.
- 18 Latrobe CJ. *Travels in North America. The American Quarterly Review*. Philadelphia: Lydia R. Bailey, 1835: pp.390-422.

- 19 West T. *treatise on pyrosis idiopathica or water-brash as contrasted with certain forms of indigestion and of organic lesions of the abdominal organs, together with the remedies dietetic and medicinal*. London: Longman, Orme, Brown, Green and Longmans, 1841.
- 20 Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? *Am J Gastroenterol* 1983;78:257-60.
- 21 Watanabe T, Urita Y, Sugimoto M, Miki K. Gastroesophageal reflux disease symptoms are more common in general practice in Japan. *World J Gastroenterol* 2007;13:4219-23.
- 22 Graham DY. Categories of patients with gastroesophageal reflux. *Arch Intern Med* 1991;151:2476.
- 23 Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. *Dig Dis Sci* 1983;28:559-63.
- 24 Graham DY. *Helicobacter pylori* and perturbations in acid secretion: the end of the beginning. *Gastroenterology* 1996;110:1647-50.
- 25 Graham DY, Dixon MF. Acid secretion, *Helicobacter pylori*, and peptic ulcer disease. In: Graham DY, Genta RM, Dixon MF (eds) *Gastritis*. Philadelphia: Lippincott Williams and Wilkins, 1999: pp.177-88.
- 26 Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, ten Kate FJ. Gastrin G. cells and somatostatin D. cells in patients with dyspeptic symptoms: *Helicobacter pylori* associated and nonassociated gastritis. *J Clin Pathol* 2005;58:927-31.
- 27 Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. *J Gastroenterol* 2010;45:1-8.
- 28 Comfort MW. Gastric acidity before and after development of gastric cancer: its etio- logic, diagnostic and prognostic significance. *Ann Intern Med* 1951;36:1331-48.
- 29 Gutierrez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY. Cure of *Helicobacter pylori* infection improves gastric acid secretion in patients with corpus gastritis. *Scand J Gastroenterol* 1997;32:664-8.
- 30 Graham DY, Shiotani A, El-Zimaity HM. Chromoendoscopy points the way to under-standing recovery of gastric function after *Helicobacter pylori* eradication. *Gastrointest Endosc* 2006;64:686-90.
- 31 Malaty HM, Kim JG, El-Zimaity HM, Graham DY. High prevalence of duodenal ulcer and gastric cancer in dyspeptic patients in Korea. *Scand J Gastroenterol* 1997;32:751-4.
- 32 Ellis FH Jr, Lyons WS, Olsen AM. The gastroesophageal sphincter mechanism: a review. *Mayo Clin Proc* 1956;31:605-14.
- 33 Hill LD, Kozarek RA. The gastroesophageal flap valve. *J Clin Gastroenterol* 1999;28:194-7.
- 34 Hill LD, Kozarek RA, Kraemer SJ, *et al*. The gastroesophageal flap valve: in vitro and in vivo observations. *Gastrointest Endosc* 1996;44:541-7.

- 35 Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. *Helicobacter pylori* infection correlates with severity of reflux esophagitis: with manometry findings. *J Gastroenterol* 1999;34:553-9.
- 36 Wong WM, Lai KC, Hui WM, *et al.* Pathophysiology of gastroesophageal reflux diseases in Chinese - role of transient lower esophageal sphincter relaxation and esophageal motor dysfunction. *Am J Gastroenterol* 2004;99:2088-93.
- 37 Zerbib F, Bicheler V, Leray V, *et al.* *H. pylori* and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. *Am J Physiol Gastrointest Liver Physiol* 2001;281:G350-G356.
- 38 Tanaka I, Tatsumi Y, Kodama T, *et al.* Effect of *Helicobacter pylori* eradication on gastro-esophageal function. *J Gastroenterol Hepatol* 2004;19:251-7.
- 39 Graham DY. *Campylobacter pylori* and Barrett's esophagus. *Mayo Clin Proc* 1988;63:1258-60.
- 40 Ruge M, Russo V, Busatto G, *et al.* The phenotype of gastric mucosa coexisting with Barrett's oesophagus. *J Clin Pathol* 2001;54:456-60.
- 41 Lanza FL, Graham DY. Bougienage is effective therapy for most benign esophageal strictures. *JAMA* 1978;240:844-7.
- 42 Patterson DJ, Graham DY, Smith JL, *et al.* Natural history of benign esophageal stricture treated by dilatation. *Gastroenterology* 1983;85:346-50.
- 43 Benedict EB, Sweet RH. Benign stricture of the esophagus. *Gastroenterology* 1948;11:618-28.
- 44 Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastro-esophageal reflux disease. *Gastroenterology* 1990;98:654-61.
- 45 Collen MJ, Johnson DA, Sheridan MJ. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy. *Dig Dis Sci* 1994;39:410-17.
- 46 Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. *Dig Dis Sd* 1994;39:1434-40.
- 47 Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and *Helicobacter pylori* status. *Gastroenterology* 1999;116:239-47.
- 48 Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. *Gastroenterology* 2009;137:80-7.
- 49 McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. *Gastroenterology* 2009;137:20-2.
- 50 Graham DY, Dore MP. Perturbations in gastric physiology in *Helicobacter pylori* duodenal ulcer: are they all epiphenomena? *Helicobacter* 1997;2(Suppl 1):S44-9.
- 51 Nakajima S, Hattori T. Active and inactive gastroesophageal reflux diseases related to *Helicobacter pylori* therapy. *Helicobacter* 2003;8:279-93.
- 52 Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of *Helicobacter pylori* in patients with gastro-oesophageal reflux disease: systematic review. *BMJ* 2003;326:737-9.

- 53 Qia B, Ma S. Effects of *Helicobacter pylori* eradication on gastroesophageal reflux disease: evidence from eleven studies. *Helicobacter* 2011;16(4):255-65.
- 54 Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. *Helicobacter pylori* eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. *Gastroenterology* 2001;121:1120-6.
- 55 Schwizer W, Thumshirn M, Dent J, et al. *Helicobacter pylori* and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. *Lancet* 2001;357:1738-42.
- 56 Laine L, Sugg J. Effect of *Helicobacter pylori* eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. *Am J Gastroenterol* 2002;97:2992-7.
- 57 Ishiki K, Mizuno M, Take S, et al. *Helicobacter pylori* eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. *Clin Gastroenterol Hepatol* 2004;2:474-9.
- 58 Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. *Helicobacter* 2010;15:486-90.
- 59 Asaka M, Kato M, Graham DY. Prevention of gastric cancer by *Helicobacter pylori* eradication. *Intern Med* 2010;49:633-6.
- 60 Graham DY. Gastric cancer surveillance or prevention plus targeted surveillance. *Jap J Helicobacter Res* 2009;10:9-14.
- 61 El-Serag HB. The epidemic of esophageal adenocarcinoma. *Gastroenterol Clin North Am* 2002;31:421-40.
- 62 El-Serag HB, Graham DY. Routine polypectomy for colorectal polyps and ablation for Barrett's esophagus are intellectually the same. *Gastroenterology* 2011;140:386-8.
- 63 Hayward J. The lower end of the oesophagus. *Thorax* 1961;16:36-41.
- 64 Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. *Ann Intern Med* 1999;130:883-90.
- 65 Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between *Helicobacter pylori* infection and esophageal neoplasia: a meta-analysis. *Clin Gastroenterol Hepatol* 2007;5:1413-17.
- 66 Graham DY. *Helicobacter pylori* is not and never was "protective" against anything, including GERD. *Dig Dis Sci* 2003;48:629-30.
- 67 Kudo M, Gutierrez O, El-Zimaity HM, et al. CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer. *J Clin Pathol* 2005;58:259-62.
- 68 Graham DY, Yamaoka Y. *H. pylori* and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. *Helicobacter* 1998; 3:145-51.
- 69 Graham DY. The only good *Helicobacter pylori* is a dead *Helicobacter pylori*. *Lancet* 1997;350:70-1.
- 70 Graham DY. Can therapy ever be denied for *Helicobacter pylori* infection? *Gastroenterology* 1997;113 6(Suppl):S113-17.



- 71 Graham DY, Opekun AR, Yamaoka Y, Osato MS, El-Zimaity HM. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. *Aliment Pharmacol Ther* 2003;17:193-200.
- 72 Graham DY, Genta RM. Long-term proton pump inhibitor use and gastrointestinal cancer. *Curr Gastroenterol Rep* 2008;10:543-7.
- 73 Kuipers EJ, Lundell L, Klinkenberg-Knol EC, *et al.* Atrophic gastritis and *Helicobacter pylori* infection in patients with reflux esophagitis treated with omeprazole or fundoplication. *N Engl J Med* 1996;334:1018-22.
- 74 Kuipers EJ, Klinkenberg-Knol EC, Vandenbroucke-Grauls CM, Appelmek BJ, Schenk BE, Meuwissen SG. Role of *Helicobacter pylori* in the pathogenesis of atrophic gastritis. *Scand J Gastroenterol* 1997;223(Suppl):28-34.
- 75 Graham DY. *Campylobacter pylori* and peptic ulcer disease. *Gastroenterology* 1989;96:615-25.
- 76 Lundell L, Havu N, Miettinen P, *et al.* Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. *Aliment Pharmacol Ther* 2006;23:639-47.
- 77 Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, *et al.* Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. *Aliment Pharmacol Ther* 2006;23:639-47.
- 78 Yang HB, Sheu BS, Wang ST, Cheng HC, Chang WL, Chen WY. *H. pylori* eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole. *Am J Gastroenterol* 2009;104:1642-9.
- 79 Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, *et al.* Cure of *Helicobacter pylori* infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. *Gut* 2004;53:12-20.
- 80 Malfertheiner P, Megraud F, O'Morain C, *et al.* Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007;56: 772-81.

## Literatura

- 1 Hvid-Jensen F, Pedersen L, Drewes AM, *et al.* Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med* 2011;365:1375-83.
- 2 Wani S, Falk G, Hall M, *et al.* Patients with nondysplastic Barrett 's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2011;9:220-7.
- 3 Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink - is intestinal metaplasia dead? *Am J Gastroenterol* 2009;104:2588-94.
- 4 Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. *Am J Gastroenterol* 2008;103:788-97.
- 5 Hirota WK, Zuckerman MJ, Adler DG, *et al.* ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. *Gastrointest Endosc* 2006;63:570-80.
- 6 Spechler SJ, Sharma P, Souza RF, *et al.* American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology* 2011;140:1084-91.
- 7 British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar - lined oesophagus. Available at: [www.BSG.org.uk](http://www.BSG.org.uk).
- 8 Vakil N, van Zanten SV, Kahrilas P, *et al.* Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900-20.
- 9 Eisen GM, Sandler RS, Murray S, *et al.* The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus' *Am J Gastroenterol* 1997;92:27-31.
- 10 Johnson DA, Winters C, Spurling TJ, *et al.* Esophageal acid sensitivity in Barrett's esophagus. *J Clin Gastroenterol* 1987;9:23-7.
- 11 Grade A, Pulliam G, Johnson C, *et al.* Reduced chemoreceptor sensitivity in patients with Barrett 's esophagus may be related to age and not to the presence of Barrett 's epithelium. *Am J Gastroenterol* 1997;92:2040-3.
- 12 Chak A, Ochs-Balcom H, Falk G, *et al.* Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. *Cancer Epidemiol Biomarkers Prev* 2006;15:1668-73.
- 13 Orloff M, Peterson C, He X, *et al.* Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. *JAMA* 2011; 306:410-19.
- 14 McClave SA, Boyce HW, Gottfried MR. Early diagnosis of the columnar-lined esophagus: a new endoscopic criterion. *Gastrointest Endosc* 1987;33:413-16.
- 15 Olman JJ, Shaheen NJ, Desai AA, *et al.* The quality of care in Barrett's esophagus: endoscopist and pathologist practices. *Am J Gastroenterol* 2001;96: 876-81.

- 16 Sharma P, Dent J, Armstrong D, *et al.* The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. *Gastroenterology* 2006;131:1392-9.
- 17 Liu W, Hahn H, Odze RD, *et al.* Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. *Am J Gastroenterol* 2009;104:816-24.
- 18 Kelty CJ, Gough MD, van Wyk Q, *et al.* Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. *Scand J Gastroenterol* 2007;42:1271-4.
- 19 Takubo K, Aida J, Naomoto Y, *et al.* Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. *Hum Pathol* 2009;4:65-74.
- 20 Wang A, Mattek NC, Corless CL, *et al.* The value of traditional upper endoscopy as a diagnostic test for Barrett's esophagus. *Gastrointest Endosc* 2008;68:859-6.
- 21 Chandrasoma PT, Der R, Dalton P, *et al.* Distribution and significance of epithelial types in columnar-lined esophagus. *Am J Surg Pathol* 2001;25:1188-93.
- 22 Harrison R, Perry I, Haddadin W, *et al.* Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. *Am J Gastroenterol* 2007;102:1154-61.
- 23 Paull A, Trier JS, Dalton MD, *et al.* The histologic spectrum of Barrett's esophagus. *N Engl J Med* 1976;295:476-80.
- 24 Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. *Gastrointest Endosc* 1996;44:91-4.
- 25 Alikhan M, Rex D, Khan A, *et al.* Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. *Gastrointest Endosc* 1999;50:23-6.
- 26 Montgomery E, Bronner MP, Goldblum JR, *et al.* Reproducibility of the diagnosis of dysplasia Barrett esophagus: a reaffirmation. *Hum Pathol* 2001;32:368-78.
- 27 Mino-Kenudson M, Hull MJ, Brown I, *et al.* EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. *Gastrointest Endosc* 2007;66:660-6.
- 28 Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? *Cancer Epidemiol Biomarkers Prev* 2010;19:1468-70.
- 29 Siegel R, Ward E, Brawley O, *et al.* Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin* 2011;61:212-36.
- 30 Sikkema M, de Jonge PJ, Steyerberg EW, *et al.* Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and metaanalysis. *Clin Gastroenterol Hepatol* 2010;8:235-44.
- 31 Anderson LA, Murray LJ, Murphy SJ, *et al.* Mortality in Barrett's oesophagus: results from a population based study. *Gut* 2003;52:1081-4.
- 32 Rice TW, Blackstone EH, Goldblum JR, *et al.* Superficial adenocarcinoma of the esophagus. *J Thorac Cardiovasc Surg* 2001;122:1077-90.

- 33 Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. *Am J Gastroenterol* 2009;104:1356-62.
- 34 Dulai GS, Guha S, Kahn KL, *et al.* Preoperative prevalence of Barrett 's esophagus in esophageal adenocarcinoma: a systematic review. *Gastroenterology* 2002;122: 26-33.
- 35 Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. *CA Cancer J Clin* 2009;59:27-41.
- 36 Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence' *Am J Gastroenterol* 2002;97:1319-27.
- 37 Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett's esophagus by endoscopy indication. *Gastrointest Endosc* 2010;71:21-7.
- 38 Jobe BA, Hunter JG, Chang EY, *et al.* Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. *Am J Gastroenterol* 2006;101:2693-703.
- 39 Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus' *Clin Gastroenterol Hepatol* 2007;5:319-25.
- 40 Sharma P Wani S, Rastogi A, *et al.* The diagnostic accuracy of esophageal capsule endoscopy in patients with gastroesophageal reflux disease and Barrett 's esophagus: a blinded, prospective study. *Am J Gastroenterol* 2008;3:525-32.
- 41 Kadri SR, Lao-Sirieix P O'Donovan M, *et al.* Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. *BMJ* 2010;341:c4372.
- 42 Stoltey J, Reeba H, Ullah N, *et al.* Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? *Aliment Pharmacol Ther* 2007;25:83-91.
- 43 Rodriguez S, Mattek N, Lieberman D, *et al.* Barrett's esophagus on repeat endoscopy: should we look more than once? *Am J Gastroenterol* 2008;103:1892-7.
- 44 Hanna S, Rastogi A, Weston AP *et al.* Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. *Am J Gastroenterol* 2006;101:1416-20.
- 45 Modiano N, Gerson LB. Risk factors for the detection of Barrett's esophagus in patients with erosive esophagitis. *Gastrointest Endosc* 2009;69:1014-20.
- 46 Inadomi JM, Sampliner R, Lagergren J, *et al.* Screening and surveillance for Barrett esophagus in high risk groups: a cost-utility analysis. *Ann Intern Med* 2003;138: 176-86.
- 47 Spechler SJ, Sharma P Souza RF, *et al.* American Gastroenterological Association technical review on the management of Barrett's esophagus. *Gastroenterology* 2011;140:e18-52.

- 48 Fitzgerald RC, Saeed I, Khoo D, *et al.* Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. *Dig Dis Sci* 2001;46:1892-8.
- 49 Abela JE, Going JJ, Mackenzie JF, *et al.* Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. *Am J Gastroenterol* 2008;103:850-5.
- 50 Levine DS, Blount PL, Rudolph RE, *et al.* Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. *Am J Gastroenterol* 2000;95:1152-7.
- 51 Reid BJ, Blount PL, Feng Z, *et al.* Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. *Am J Gastroenterol* 2000;95:3089-6.
- 52 Peters FP, Brakenhoff KP, Curvers WL, *et al.* Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. *Gastrointest Endosc* 2008;67:604-9.
- 53 Komanduri S, Swanson G, Keefer L, *et al.* Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies. *Gastrointest Endosc* 2009;70:1072-8.
- 54 Curvers WL, ten Kate FJ, Krishnadath KK, *et al.* Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. *Am J Gastroenterol* 2010;105:1523-30.
- 55 Wani S, Falk GW, Post J, *et al.* Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. *Gastroenterology* 2011;141:1179-86.
- 56 Buttar NS, Wang KK, Sebo TJ, *et al.* Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. *Gastroenterology* 2001;120:1630-9.
- 57 Tharavej C, Hagen JA, Peters JH, *et al.* Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. *Surg Endosc* 2006;20:439-43.
- 58 Prasad GA, Wang KK, Buttar NS, *et al.* Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. *Gastroenterology* 2007;132:1226-33.
- 59 Corley DA, Levin TR, Habel LA, *et al.* Surveillance and survival in Barrett's adenocarcinomas: a population-based study. *Gastroenterology* 2002;122:633-40.
- 60 Van Sandick JW, Lanschot JJ, Kuiken BW, *et al.* Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. *Gut* 1998;43:216-22.
- 61 Das D, Ishaq S, Harrison R, *et al.* Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. *Am J Gastroenterol* 2008;103:1079-89.
- 62 Abrams JA, Kapel RC, Lindberg GM, *et al.* Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. *Clin Gastroenterol Hepatol* 2009;7:736-42.
- 63 Ngamruengphong S, Sharma VK, Das A. Diagnostic yield of methylene blue chromo-endoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis. *Gastrointest Endosc* 2009;69:1021-8.

- 64 Curvers W, Baak L, Kiesslich R, *et al.* Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. *Gastroenterology* 2008;134:670-9.
- 65 Song LM, Adler DG, Conway JD, *et al.* Narrow band imaging and multiband imaging. *Gastrointest Endosc* 2008;67:581-9.
- 66 Curvers WL, van den Broek FJ, Reitsma JB, *et al.* Systematic review of narrow-band imaging for the detection and differentiation of abnormalities in the esophagus and stomach. *Gastrointest Endosc* 2009;69:307-17.
- 67 Kantsevoy SV, Adler DG, Conway JD, *et al.* Confocal laser endomicroscopy. *Gastrointest Endosc* 2009;70:197-200.
- 68 Dunbar KB, Okolo P, Montgomery E, *et al.* Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. *Gastrointest Endosc* 2009; 70:645-54.
- 69 Sharma P, Meining A, Coron E, *et al.* Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. *Gastrointest Endosc* 2011;74:465-72.
- 70 Falk GW. Risk factors for esophageal cancer development. *Surg Oncol Clin North Am* 2009;18:469-85.
- 71 Hameeteman W, Tytgat GN, Houthoff HJ, *et al.* Barrett's esophagus: development of dysplasia and adenocarcinoma. *Gastroenterology* 1989;96:1249-56.
- 72 Sharma P, Falk GW, Weston AP, *et al.* Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. *Clin Gastroenterol Hepatol* 2006;4: 566-72.
- 73 Reid BJ, Haggitt RC, Rubin CE, *et al.* Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. *Gastroenterology* 1987;93:1-11.
- 74 Reid BJ, Blount PL, Rubin CE, *et al.* Flow-cytometric and histological progression to malignancy in Barrett 's esophagus: prospective endoscopic surveillance of a cohort. *Gastroenterology* 1992;102:1212-19.
- 75 Reid BJ. P53 and neoplastic progression in Barrett's esophagus. *Am J Gastroenterol* 2001;96:1321-3.
- 76 Prevo LJ, Sanchez CA, Galipeau PC, *et al.* P53-mutant clones and field effects in Barrett's esophagus. *Cancer Res* 1999;59:4784-7.
- 77 Wong DJ, Barrett MT, Stoger R, *et al.* p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. *Cancer Res* 1997; 57:2619-22.
- 78 Reid BJ, Levine DS, Longton G, *et al.* Predictors of progression to cancer in Barrett 's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. *Am J Gastroenterol* 2000;95:1669-76.
- 79 Dunn JM, Mackenzie GD, Oukrif D, *et al.* Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. *Br J Cancer* 2010;102:1608-17.

- 80 Fritcher EG, Brankley SM, Kipp BR, *et al.* A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. *Hum Pathol* 2008;39:1128-35.
- 81 Reid BJ, Prevo LJ, Galipeau PC, *et al.* Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. *Am J Gastroenterol* 2001;96:2839-48.
- 82 Wong DJ, Paulson TG, Prevo LJ, *et al.* p16INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. *Cancer Res* 2001;61:8284-9.
- 83 Schulmann K, Sterian A, Berki A, *et al.* Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. *Oncogene* 2005;24:4138-48.
- 84 Wang JS, Guo M, Montgomery EA, *et al.* DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. *Am J Gastroenterol* 2009;104:2153-60.
- 85 Galipeau PC, Li X, Blount PL, *et al.* NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. *PLoS Med* 2007;4:e67.
- 86 Sato F, Jin Z, Schulmann K, *et al.* Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. *PLoS ONE* 2008;3:e1890

## Literatura

- 1 Rex DK, Cummings OW, Shaw M. Screening for Barrett 's esophagus in colonoscopy patients with and without heartburn. *Gastroenterology* 2003;125(6):1670-7.
- 2 Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. *Am J Med* 2001;111(1):33-7.
- 3 Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. *Am J Gastroenterol* 2008;103:788-97.
- 4 Menon D, Stafinski T, Wu H, Lau D, Wong C. Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. *BMC Gastroenterology* 2010;10:111.
- 5 Shaheen NJ, Sharma P, Overholt BF, *et al.* Radiofrequency ablation in Barrett's esophagus with dysplasia. *N Engl J Med* 2009;360(22):2277-88.
- 6 Seewald S, Akaraviputh T, Seitz U, *et al.* Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. *Gastrointest Endosc* 2003;57:854-9.
- 7 Peters FP, Kara MA, Rosmolen WD, *et al.* Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. *Am J Gastroenterol* 2006;101:1449-57.
- 8 Wani S, Sayana H, Sharma P. Endoscopic eradication of Barrett's esophagus. *Gastrointest Endosc* 2010;71(1):147-66.
- 9 Attil T, Faigel DO. Role of endoscopic ultrasound in superficial esophageal cancer. *Dis Esophagus* 2009;22(2):104-12.
- 10 Stein HJ, Feith M, Bruecher BL, *et al.* Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. *Ann Surg* 2005;242:566-75.
- 11 Altorki NK, Lee PC, Liss Y, *et al.* Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. *Ann Surg* 2008;247:434-9.
- 12 Pennathur A, Farkas A, Krasinskas AM, *et al.* Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. *Ann Thorac Surg* 2009;87:1048-55.
- 13 Buskens CJ, Westerterp M, Lagarde SM, *et al.* Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. *Gastrointest Endosc* 2004;60:703-10.
- 14 Namasivayam V, Wang KK, Prasad GA. Endoscopic mucosal resection in the management of esophageal neoplasia: current status and future directions. *Clin Gastroenterol Hepatol* 2010;8(9):743-54.



- 15 Zuckerman MJ, Hirota WK, Adler DG, *et al.* ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. *Gastrointest Endosc* 2005;61:189-94.
- 16 Vikneswaran N, Lutzke LS, Prasad GA, *et al.* Bleeding and thrombotic risk in endoscopic mucosal resection (EMR) with dopidogrel. *Gastrointest Endosc* 2010;71:AB126.
- 17 Buttar NS, Wang KK, Sebo TJ, *et al.* Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. *Gastroenterology* 2001;120(7):1630-9.
- 18 Curvers WL, Herrero LA, Wallace MB, *et al.* Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. *Gastroenterology* 2010;139(4):1106-14.
- 19 May A, Gossner L, Behrens A, *et al.* A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. *Gastrointest Endosc* 2003;58:167-75.
- 20 Abrams JA, Fedi P, Vakiani E, *et al.* Depth of resection using two different endoscopic mucosal resection techniques. *Endoscopy* 2008;40:395-9.
- 21 Esaki M, Matsumoto T, Hirakawa K, *et al.* Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. *Endoscopy* 2007;39:41-5.
- 22 Prasad GA, Wu TT, Wigle DA, *et al.* Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. *Gastroenterology* 2009;137:815-23.
- 23 Kodama M, Kakegawa T. Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. *Surgery* 1998;123:432-9.
- 24 Pech O, Behrens A, May A, *et al.* Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. *Gut* 2008;57: 1200-6.
- 25 Wang KK, Lutzke L, Borkenhagen L, *et al.* Photodynamic therapy for Barrett's esophagus: does light still have a role? *Endoscopy* 2008;40(12):1021-5.
- 26 Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. *Gastrointest Endosc* 2000;52(3):328-32.
- 27 Pech O, May A, Rabenstein T, Ell C. Endoscopic resection of early oesophageal cancer. *Gut* 2007;56(11):1625-34.
- 28 Ell C, May A, Pech O, *et al.* Curative endoscopic resection of early esophageal adeno-carcinomas (Barrett's cancer). *Gastrointest Endosc* 2007;65(1):3-10.
- 29 Van Vilsteren FG, Bergman JJ. Endoscopic therapy using radiofrequency ablation for esophageal dysplasia and carcinoma in Barrett's esophagus. *Gastrointest Endosc Clin North Am* 2010;20(1):55-74.

- 30 Konda VJ, Ross AS, Ferguson MK, *et al.* Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? *Clin Gastroenterol Hepatol* 2008;6(2):159-64.
- 31 Shaheen NJ, Frantz DJ. When to consider endoscopic ablation therapy for Barrett's esophagus. *Curr Opin Gastroenterol* 2010;26(4):361-6.
- 32 Li LB, Xie JM, Zhang XN, *et al.* Retrospective study of photodynamic therapy vs photodynamic therapy combined with chemotherapy and chemotherapy alone on advanced esophageal cancer. *Photodiagn Photodynam Ther* 2010;7(3):139-43.
- 33 Prasad GA, Wang KK, Buttar NS, *et al.* Long term survival following endoscopic and surgical treatment of high grade dysplasia in Barrett 's esophagus. *Gastroenterology* 2007;132:1226-33.
- 34 Bellnier DA, Greco WR, Loewen GM, *et al.* Population pharmacokinetics of the photodynamic therapy agent 2-1-hexyloxyethyl -2-devinyl pyropheophorbide-a in cancer patients. *Cancer Res* 2003;63(8):1806-13.
- 35 Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Lutzke LS, Borkenhagen LS. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. *Gastrointest Endosc* 2007;65(1):60-6.
- 36 Rangunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. *Scand J Gastroenterol* 2005;40(7):750-8.
- 37 Overholt BF, Wang KK, Burdick JS, *et al.* Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett 's high-grade dysplasia. [see comment]. *Gastrointest Endosc* 2007;66(3):460-8.
- 38 Overholt B, Lightdale C, Wang K, *et al.* Photodynamic therapy (PDT) with porfimer sodium for the ablation of highgrade dysplasia in Barrett 's esophagus (BE): international, partially blinded randomized phase III trial ' *Gastrointest Endosc* 2005;62: 488-98.
- 39 Prasad GA, Wang KK, Halling KC, *et al.* Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. *Cancer* 2008;113(3):470-6.
- 40 Ishihara R, Iishi H, Uedo N, *et al.* Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. *Gastrointest Endosc* 2008;68(6):1066-72.
- 41 Muto M, Miyamoto S, Hosokawa A. Endoscopic mucosal resection in the stomach using the insulated-tip needle-knife. *Endoscopy* 2005;37(2):178-82.
- 42 Oka S, Tanaka S, Kaneko I, *et al.* Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. *Gastrointest Endosc* 2006;64(6): 877-83.
- 43 Johnston MH, Eastone JA, Horwhat JD. Cryoablation of Barrett's esophagus: a pilot study. *Gastrointest Endosc* 2005;62(6):842-8.
- 44 Greenwald BD, Dumot JA, Abrams JA, *et al.* Endoscopic spray cryoablation for esophageal cancer: safety and efficacy. *Gastrointest Endosc* 2010;71(4):686-93.

- 45 Shaheen NJ, Greenwald BD, Peery AF, *et al.* Safety and efficacy of endoscopic spray cryoablation for Barrett 's esophagus with high-grade dysplasia. *Gastrointest Endosc* 2010;71(4):680-5.
- 46 Greenwald BD, Dumot JA, Horwhat JD. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryoablation in the esophagus. *Dis Esophagus* 2010;23(1):13-19.
- 47 Attwood SE, Lewis CJ, Caplin S, Hemming K, Armstrong G. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. *Clin Gastroenterol Hepatol* 2003;1:258-63.
- 48 Dulai GS, Jensen DM, Cortina G, Fontana L, Ippoliti A. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. *Gastrointest Endosc* 2005;61(2):232-40.
- 49 Sharma P, Wani S, Weston AP, *et al.* A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. *Gut* 2006;55(9): 1233-9.
- 50 Stewart F, Baas P Star W. What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? *Radiat Oncol* 1998;48:233-48.
- 51 Pech O, Gossner L, May A, Ell C. Management of Barrett's oesophagus, dysplasia and early adenocarcinoma. *Best Pract Res Clin Gastroenterol* 2001;15(2):267-84.
- 52 Wang KK, Prasad G, Tian J. Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. *Curr Opin Gastroenterol* 2010;26(5):453-8.